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Abstract 
Serotonin (5-HT) is a neurotransmitter with an integral role in regulating mood. 
Dysregulation of this system is implicated in disorders such as depression and withdrawal 
from drugs of abuse.  3,4- methylenedioxymethamphetamine (MDMA) or ‘Ecstasy’ is a 
commonly abused drug which primarily targets the serotonin transporter (SERT) and 
competes with 5-HT for uptake into the pre-synaptic neuron.  This study focused on the 
cellular effects MDMA has on SERT, and how it is able to regulate SERT function.  Previous 
studies have shown that MDMA is able to down-regulate SERT expression from the cell 
surface to intracellular vesicles, thereby decreasing 5-HT transport.  How MDMA targets this 
regulatory pathway is unclear.  Protein Kinase C (PKC) is a well-known regulator of SERT, 
and activation of PKC causes phosphorylation of SERT, targeting the transporter for 
internalization.  Using rotating disc electrode voltammetry (RDEV) we show that MDMA 
causes a significant functional decrease of SERT in HEK-293 and N2A cells expressing GFP-
hSERT.  This MDMA-induced down-regulation was not observed when cells were pretreated 
with PKC inhibitor, Bis I.  This data suggests that the MDMA-induced down-regulation of 
SERT occurs via PKC signaling pathways.  Further investigations into the kinetics of the 
serotonin transporter did not show a change in the Vmax or Km values between the control and 
the MDMA-treated samples.  This suggests that the functional down-regulation observed 
after MDMA treatment was not due to a decrease in SERT expression at the cell surface.   
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1 Chapter 1: Introduction 
1.1 Drugs of Abuse 
In New Zealand it is estimated that 30% of the population abuse drugs such as nicotine, 
alcohol, psychostimulants and opioids (M.O.H. 2007), which have a large impact on social 
and economic costs.  Currently there are no pharmacotherapies available to treat abuse of 
psychostimulants such as cocaine, ecstasy, amphetamine or methamphetamine.  The 2010 
World Drug Report states that the Oceania region has one of the highest annual prevalence 
rates of ecstasy, with New Zealand reporting a 2.6% rate of annual prevalence in a population 
of 15-64 year olds (UNODC 2010). Drug abuse and dependence is of major concern with 
further research needed to determine the mechanistic effect drugs of abuse have on the brain 
so that potential therapeutics that prevent or reverse these changes can be investigated.  
1.2 The Reward Pathway 
The natural reward pathway in the brain is activated upon events such as eating, drinking or 
sex (Adinoff 2004). It is targeted by drugs of abuse which leads to a dysregulation of the 
neuro-circuitry involved (Koob 2001).  Dopaminergic neurons make up the core of this 
natural reward system, with other monoamine systems such as the serotonergic system 
feeding into it, creating what is known as the limbic pathway.  The ventral tegmental area is 
the center of the pathway, with dopamine cell bodies located here which project forward to 
the basal forebrain.  The basal forebrain consists of the nucleus accumbens (NAc), pre-frontal 
cortex (PFC) and amygdala which all play a role in reward stimuli (Robinson and Berridge 
2000).  Figure 1:1 shows how the serotonergic system innervates the limbic system with cell 
bodies located in the raphe nuclei (RN) which project forward to the forebrain (Hensler 
2006). 
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Figure 1:1: The brain’s natural reward pathway.  
The serotonergic system in the brain’s natural reward pathway consists of serotonergic 
neuronal cell bodies located in the dorsal raphe nuclei (RN).  These neurons project forward 
to the ventral tegmental area (VTA) where dopaminergic cell bodies are located and make up 
the core of the limbic pathway.  The serotonergic system has neurons which then feed into 
and innervate the prefrontal cortex (PFC), nucleus accumbens (NAc), striatum, amygdala and 
hippocampus creating the serotonergic pathway involved in natural reward and drug abuse.  
Adapted from www.cnsforum.com (Lundbeck Institute).  
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1.3 Serotonin 
Serotonin (5-HT) is a monoamine neurotransmitter located in the brain and non-neuronal 
tissues such as the placenta, intestinal epithelial cells and platelets (Hoyer et al. 2002; 
Murphy et al. 2004; Jayanthi and Ramamoorthy 2005).  In the brain, the serotonergic system 
(Figure 1:1) projects from the raphe nuclei in the brainstem, feeding into the ventral 
tegmental area with neurons extending to the pre-frontal cortex, basal ganglia, including the 
nucleus accumbens and striatum, as well as innervating the hippocampus and amygdala 
(Howell and Kimmel 2008).  An individual’s emotional response is partly regulated by the 
serotonergic tone which is determined by the levels of 5-HT in the brain.  5-HT plays an 
important role in the modulation of mood, sleep, appetite, anxiety and reward (Howell and 
Kimmel 2008; Murphy et al. 2008).  Altered 5-HT signaling leads to an imbalance in 5-HT 
levels and is implicated in mood disorders such as depression and anxiety (Owens and 
Nemeroff 1994; Lesch et al. 1996), as well as other conditions such as obsessive compulsive 
disorder, alcoholism and substance abuse (Melo et al. 1996; Hoyer et al. 2002).   
1.4 Biochemistry of 5-HT 
5-HT synthesis is catalyzed by tryptophan hydroxylase (TPH), an enzyme which converts 
tryptophan to 5-hydroxytryptophan (5-HTP).  5-hydroxytryptophan is then converted to 5-HT 
by the enzyme hydroxytryptophan decarboxylase (HDC).  As shown in Figure 1:2, 5-HT is 
stored in secretory vesicles within serotonergic neurons to prevent degradation by 
monoamine oxidases (MAO) located on mitochondria (Jorgensen 2007; Nichols and Nichols 
2008).  An action potential which depolarizes the nerve cell leads to an influx of calcium, 
causing vesicle release.  5-HT is released from the pre-synaptic nerve terminal into the 
synaptic cleft where it binds to 5-HT receptors located on the pre- and post-synaptic 
membranes.  Binding to the receptors on the post-synaptic membrane causes the cell to 
depolarize, propagating the action potential down the neuron.  Second messenger signaling 
systems are subsequently triggered and become activated in such a way that the signal is 
chemically propagated down the post-synaptic neuron (Hoffman et al. 1998; Nichols and 
Nichols 2008).  5-HT is cleared from the synaptic cleft either by diffusion or re-uptake by the 
serotonin transporter (SERT) located on the pre-synaptic membrane.  These transporters 
effectively terminate further 5-HT signaling.  Upon entry back into the pre-synaptic cell, 5-
HT is either recycled into synaptic vesicles for future re-release or targeted for degradation by 
monoamine oxidases (MAO).  MAO A and B are the primary enzymes for degradation of 5-
4 
 
HT via deamination into its metabolite 5-hydroxyindoleacetic acid (5-HIAA) (Nichols and 
Nichols 2008).    
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Figure 1:2: Biochemical pathway of 5-HT 
5-HT is synthesized via a series of enzyme-mediated steps with the final product being stored 
in secretory vesicles in the pre-synaptic terminal.  An action potential depolarizes the 
terminal leading to an influx of Ca
2+
, which causes the vesicles to be released into the 
synaptic cleft.  5-HT binds to receptors located on the pre- and post-synaptic terminals.  5-HT 
binding to the post-synaptic receptors causes the terminal to become depolarized therefore 
propagating the action potential.  Activation of second messenger systems are triggered in the 
post-synaptic terminal.  SERT is responsible for reuptake of 5-HT from the synaptic cleft, 
effectively terminating 5-HT function.  Following uptake by SERT, 5-HT is recycled into 
vesicles or is targeted for degradation by monoamine oxidases.  Key: 5-HT, 5-
hydroxytryptamine; SERT, serotonin transporter; 5-HTR, 5-HT receptor; Ca
2+
, calcium ions.  
Figure adapted from Nichols et al. (2008). 
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1.5 5-HT receptors 
1.5.1 Overview of receptor subtypes 
Once in the synapse, 5-HT binds to and activates 5-HT receptors located on the post-synaptic 
membrane.  5-HT auto-receptors located on the pre-synaptic membrane can also respond to 
5-HT and play a role in regulating synthesis and release within the pre-synaptic neuron 
(Nichols and Nichols 2008).  There are seven different types of 5-HT receptors; six belong to 
the G-protein coupled receptor (GPCR) family, and one, 5-HT3, is an ion channel (Nichols 
and Nichols 2008).  There are 15 subtypes of 5-HT receptors which include 5-HT1A, 5-HT1B, 
5-HT1D, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3A, 5-HT3B, 5-HT4, 5-HT5A, 5-HT5B, 
5-HT6 and 5-HT7.  G-protein coupled receptors are the largest family of signaling receptors 
and become activated by a vast array of extracellular ligands.  They are able to relay the 
signal down through many second messenger signaling cascades in the cytoplasm 
(Marinissen and Gutkind 2001). 
1.5.2 G-protein activation 
5-HT receptors are coupled to different types of G-proteins, which when activated, dissociate 
from the GPCR and interact with effector molecules which further stimulate downstream 
biochemical signaling pathways.  Activation of stimulatory G-proteins (Gs) by binding of 5-
HT to specific receptor subtypes leads to activation of an enzyme called adenylate cyclase 
(AC) which converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate 
(cAMP).  cAMP is an intracellular second messenger which interacts with target effector 
molecules such as Protein Kinase A (PKA), an important signaling protein.  Effector 
molecules of Gs-proteins are known to regulate calcium ion influx and membrane 
excitability, and PKA is able to phosphorylate specific target proteins leading to changes in 
gene expression (Nichols and Nichols 2008). 
Activation of 5-HT receptors coupled to inhibitory G-proteins (Gi) leads to an inhibition of 
AC.  This results in a decreased cAMP production and subsequent decrease in PKA activity.  
Activation of these types of GPCR causes membrane hyper-polarisation which decreases the 
rate of neuronal firing (Nichols and Nichols 2008). 
The other type of G-proteins act to cleave membrane phosphoinositides leading to formation 
of diacylglycerol (DAG) and inositol phosphates such as inositol triphosphate (IP3).  These 
molecules, along with cAMP, lead to downstream stimulation of Protein Kinase C (PKC) and 
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p38 MAPKs which are important effector molecules.  IP3 also stimulates an increase in 
intracellular Ca
2+
  levels adding to the second messenger effect (Nichols and Nichols 2008). 
1.5.3 5-HT receptor subtypes: 
The different 5-HT receptor subtypes and their important functions are outlined in Table 1:1.  
Homeostasis of 5-HT is maintained through an intricate balance between receptor activation 
of stimulatory and inhibitory G-proteins.  Disruption of this system leads to changes in 
second messenger pathways which inadvertently affect the phosphorylation of effector 
molecules such as PKC, p38MAPK, PKA and PKG, among others.  Dysregulation of this 
system is implicated in a host of mood disorders related to changes in the phosphorylation 
state of SERT (Murphy et al. 2008). 
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Table 1:1: Overview of 5-HT receptor subtypes.   
Literature review of 5-HT receptor characteristics from Nichols et al. (2008) and Jorgensen et 
al. (2007) 
Receptor 
class 
Receptor 
subtype 
Location G-
protein 
Effector 
molecules 
Function 
5-HT1 5-HT1A Pre- and 
post-
synaptic 
Gi Decreases 
cAMP, 
decreases PKA 
Membrane hyper-polarisation, 
inhibits neuronal firing, 
facilitates psychostimulant 
addiction 
 5-HT1B Pre-
synaptic 
Gi Decreases 
cAMP, 
decreases PKA 
Learning and memory 
 5-HT1D  Gi Decreases 
cAMP, 
decreases PKA 
Target for anti-migraine therapy 
 5-HT1E  Gi Decreases 
cAMP, 
decreases PKA 
Cognition and memory processes 
 5-HT1F  Gi Decreases 
cAMP, 
decreases PKA 
Target for anti-migraine therapy 
5-HT2 5-HT2A Pre- and 
post-
synaptic 
Gq Increases Ca, 
DAG, IP3 
Membrane depolarization, 
vasoconstriction, synaptic 
plasticity 
 5-HT2B  Gq Increases Ca, 
DAG, IP3 
Behavioral, auditory system, 
heart and brain development 
 5-HT2C  Gq Increases Ca, 
DAG, IP3 
Appetite, target for treating 
psychostimulant abuse, anxiety 
5-HT3 5-HT3A    Cation-selective ion channel 
 5-HT3B    Cation-selective ion channel 
5-HT4   Gs Increases 
cAMP, 
increases PKA 
Calcium ion influx, long-term 
depression (LTD), learning and 
memory 
5-HT5 5-HT5A  Gi Decreases 
cAMP, 
decreases PKA 
Higher cortical and limbic 
functions 
 5-HT5B   Unknown  
5-HT6  Post-
synaptic 
Gs Increases 
cAMP, 
increases PKA 
Higher cognitive processes, 
target for Alzheimer’s and 
schizophrenia treatment 
5-HT7   Gs Increases 
cAMP, 
increases PKA 
Sleep patterns, circadian rhythm 
and regulation of overall mood 
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1.6 The Serotonin Transporter: 
Along with the dopamine (DAT) and norepinephrine (NET) transporter, SERT belongs to the 
Na
+
/Cl
- 
coupled transporter family (Nelson 1998).  These transporters exploit the sodium 
gradient that already exists across the cell membrane to drive transport of neurotransmitters 
from the synaptic cleft back into the pre-synaptic compartment (Murphy et al. 2004; Sitte and 
Freissmuth 2010).  The primary function of SERT is to re-accumulate released 5-HT from the 
synaptic cleft, therefore, effectively terminating signaling caused by 5-HT.  The Na
+
/Cl
-
 
gradient drives this secondary active-transport mechanism and it is the most rapid and 
economical way to remove and recycle 5-HT (Murphy et al. 2004; Sitte and Freissmuth 
2010).  As well as being expressed in serotonergic neurons in the central nervous system, 
SERT is distributed in the peripheral tissue.  SERT is expressed in gastrointestinal cells, 
placental tissue, lungs and in red blood cells and platelets (Ramamoorthy et al. 2011).  
1.6.1 Structure of SERT: 
It is predicted that SERT consists of 12 hydrophobic transmembrane domains, with 
intracellular cytoplasmic NH2 and COOH termini, and a binding site located on the 
extracellular loop.  Crystal structures of the bacterial homolog, LeuTAa, have allowed further 
insight into the conformation and transport process of the monoamine transporters.  Although 
the overall homology is low with only 20-25% identical residues, the conservation around the 
binding site is high (50% identical) (Yamashita et al. 2005; Sitte and Freissmuth 2010).  It is 
thought that in SERT undergoes a conformational change following the simultaneous binding 
of Na
+
, Cl
- 
and 5-HT.  This allows 5-HT molecules to be transferred from the synapse into the 
cytosol. Once the three molecules are liberated from the binding site, K
+
 takes their place, 
allowing the transporter to return back to their original conformation (Murphy et al. 2004).  
The maintenance of the ion gradient across the cell membrane by Na
+
-K
+
-ATPases is crucial 
for the SERT transport process.  Quaternary structure evidence supports the formation of 
dimers or higher-ordered oligomers of the SERT molecules (Kilic and Rudnick 2000; Sitte et 
al. 2004).  Some studies show evidence that the transport process is not affected when the 
transporter molecule is rendered monomeric (Scholze et al. 2002), whereas others argue that 
the oligomeric structure is necessary, especially for the action of amphetamines and related 
drugs on the monoamine transporters (Sitte and Freissmuth 2010).  Oligomer formation has 
also shown to be necessary for correct exiting from the endoplasmic reticulum and travelling 
the secretory pathway to the plasma membrane (Sitte and Freissmuth 2010). 
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1.6.2 Genetic Variance of the SERT gene 
Coded by the SLC6A4 gene, the human SERT gene is comprised of fourteen exons encoding 
a protein of 630 amino acids (Murphy et al. 2004).  There is a polymorphic region upstream 
of the transcription start site which is termed the 5-HTT gene-linked polymorphic region 
(5HTTLPR).  There are two variants of this polymorphism that differentially modulate 
transcriptional activity of the SERT promoter termed the ‘short’ or ‘S’ allele or ‘long’ or ‘L’ 
allele.  These are composed of either fourteen or sixteen repeated elements respectively. 
Identification of variants in the SERT coding region have been implicated in the anxiety and 
mood disorders (Murphy et al. 2004).  This illustrates the significance of impaired regulation 
and the implication that is has in human disease conditions.  The S allele is associated with 
decreased expression of SERT at the cell surface and decreased 5-HT uptake. The 
relationship between the low expressing S variant of the 5-HTTLPR and correlation to drug 
abuse and mental disorders is poorly understood (Ramamoorthy et al. 1993).   
1.6.3 SERT and Mood Disorders 
Dysfunction of the SERT protein is implicated in many mood disorders such as depression 
and anxiety, as well as being associated with substance abuse (Murphy et al. 2004; 
Ramamoorthy et al. 2011).  Selective serotonin reuptake inhibitors (SSRI), such as fluoxetine 
(Prozac
TM
), citalopram (Celexa
TM
), paroxetine (Paxil
TM
) and sertraline (Zoloft
TM
), act as 
SERT antagonists.  By binding to SERT they effectively prevent 5-HT re-uptake and cause 
an increase in 5-HT in the synapse.  SSRI’s are therefore the most commonly prescribed drug 
to treat depression.  Response to SSRI’s varies between individuals with no certain 
explanation as to why some patients respond better than others.  An association between the 
SERT 5HTTLPR polymorphism and therapeutic response to SSRI’s has been postulated.  A 
study showed that possessing the ‘L’ allele was predictive of a better antidepressant efficacy 
in patients with symptoms of mood and anxiety disorders (Murphy et al. 2004).  Further 
pharmacogenetic studies are needed before a clinical use for 5HTTLPR genotyping is 
considered relevant. 
Drugs of abuse similarly act as SERT substrates.  3 4-methylenedioxymethamphetamine 
(MDMA) or ‘Ecstasy’, is able to bind to SERT where it is then transported inside the 
cytoplasm and able to exert complex cellular effects (see Section 1.8 MDMA).  Long-term 
use of drugs of abuse can lead to symptoms resembling those of the mood disorders 
mentioned above. 
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1.7 Regulation of SERT: 
Monoamine transporter cell surface expression and function is regulated through a series of 
post-translational modifications, including changes in the state of glycosylation and/or 
phosphorylation (Jayanthi and Ramamoorthy 2005).  The importance in understanding the 
cellular mechanisms responsible for the regulatory processes of SERT is highlighted by the 
fact that this transporter is a key controller of 5-HT signaling and is involved in disease states 
as well as being a target for therapeutic drugs and psychostimulants (Ramamoorthy et al. 
2011).  Consensus sites for the binding of protein kinases and putative interactive motifs have 
been identified in the SERT protein, illustrating the role in which second-messenger systems 
play in post-translational regulation of SERT (Jayanthi and Ramamoorthy 2005).   
One key molecular mechanism which will be focused on in this study is how the expression 
and functional properties of SERT are affected by transporter phosphorylation and how drugs 
of abuse interfere with this process (see Section 1.8 MDMA).  Several kinase cascades are 
implicated in the regulation of SERT (Ramamoorthy et al. 2011). They help to maintain a 
relationship between transporter phosphorylation state, the level of 5-HT transport and SERT 
cell surface expression.  It is suggested that increases in SERT phosphorylation at the 
membrane provides a signal for internalization of the protein, a change in the catalytic state 
of SERT, or both. It is not clear whether phosphorylation of the intracellular pool of SERT 
slows down recycling of the protein to the membrane or if the trafficking events of SERT are 
redirected to alter surface expression (Kivell et al. 2010).  Substrate and antagonist binding 
act to influence transporter phosphorylation, trafficking and interaction with transporter-
associating proteins, which all act to alter transport activity (Jayanthi and Ramamoorthy 
2005; Ramamoorthy et al. 2011).  Some of the key kinase proteins that are known to be 
involved in SERT regulation are outlined below, Figure 1:3 shows a schematic diagram of 
the interaction between the various kinase proteins: 
1.7.1 PKC 
PKC has been shown to contribute to diverse biochemical processes within the 5-HT nerve 
terminal.  These mechanisms include the acceleration of neurite extension during 
development, the enhancement of vesicular neurotransmitter release, and the modulation of 
5-HT transporter activity (Qian et al. 1997; Kramer et al. 1998).  Activation of the 5-HT2,4,6,7 
receptors causes cleavage of the membrane-bound phosphatidylinositol biphosphate (PIP2) 
protein into IP3 and DAG which act as effector molecules.  IP3 raises the levels of 
intracellular Ca
2+
 which then binds to PKC in the cytoplasm, causing the kinase to translocate 
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to the plasma membrane.  The presence of DAG in the inner portion of the lipid bilayer 
stabilizes the interaction of PKC at the membrane and supports its catalytic state so that it can 
phosphorylate its target i.e. SERT (Kramer et al. 1998). 
PKC activation is correlated with an increased level of SERT phosphorylation which causes a 
reduction in both SERT function and cell surface expression (Qian et al. 1997; Jayanthi and 
Ramamoorthy 2005; Jayanthi et al. 2005; Samuvel et al. 2005).  Efforts into the study of the 
time-dependent molecular events associated with PKC activation have shown that regulation 
of SERT occurs in a biphasic manner.  The initial phase occurs upon phosphorylation of a 
serine residue where a change in transporter function occurs causing a decrease in 5-HT 
uptake.  This decrease in SERTs catalytic activity occurs independently of trafficking and 
occurs in a rapid manner (within <5 min).  The second phase occurs when there is subsequent 
phosphorylation on a threonine residue which causes a loss of SERT from the cell surface via 
internalization.  This phase occurs between the 5 and 60 min time period (Jayanthi et al. 
2005). 
1.7.2 MAPK’s 
The mitogen-activated protein kinase (MAPK) pathway includes several serine-threonine 
protein kinases which are composed of three hierarchical proteins; MAPKK kinase 
(MAPKKK), which then phosphorylates a MAPK kinase (MAPKK), which in turn 
phosphorylates and activates a MAPK.  This signaling cascade is activated through ligand 
binding to the receptor at the plasma membrane where the signal is then transmitted 
downstream until a MAPK is activated.  Types of MAPK that have been characterized in 
detail include extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs) 
and p38 MAPKs.   These further regulate transcription factor activity or kinases downstream 
by phosphorylation, therefore altering gene regulation and other cellular processes (Ichijo 
1999). 
p38 MAPK is a particular  protein of interest as its downstream targets include the SERT 
protein.  It plays a role in a range of cellular functions including growth and differentiation as 
well as apoptosis.  It is activated by inflammatory cytokines and cellular stresses such as 
ultra-violet (UV) light.  The signal is relayed by the cell surface receptor to a divergent array 
of MAPKKK which activate two MAPKK proteins; MAPKK3 and MAPKK6.  When the 
signal reaches p38 MAPK it activates it and in response, downstream targets are 
phosphorylated (Ichijo 1999).  SERT activity is increased in response to p38 MAPK 
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activation, with an increase in 5-HT transport, but no change in  SERT trafficking observed 
(Samuvel et al. 2005).  Inhibition of p38 MAPK leads to a decrease in 5-HT uptake but no 
change in SERT cell surface expression (Zhu et al. 2005).  These results suggest that p38 
MAPK plays a role in maintaining SERT basal phosphorylation, expression and function 
(Samuvel et al. 2005).  Cellular stress affect SERT and subsequently 5-HT signaling and p38 
MAPK is induced by stress.  It is plausible that p38 MAPK-mediated SERT regulation may 
provide a novel pre-synaptic mechanism whereby 5-HT synaptic levels are maintained during 
stressful conditions (Ramamoorthy et al. 2011).  The MAPK pathway can be activated from 
upstream PKC, but can also be activated independent of PKC through PKA (Marinissen and 
Gutkind 2001). 
There is evidence supporting both trafficking-dependent and independent mechanisms of p38 
MAPK-mediated SERT regulation (Ramamoorthy et al. 2011). Taking into consideration that 
activation of PKC increases SERT phosphorylation and rate of internalization, and inhibition 
of p38 MAPK decreases SERT basal phosphorylation and membrane insertion, these two 
kinases must work on different phosphorylation sites.  These two kinases may directly 
phosphorylate SERT, but at different cellular locations (Ramamoorthy et al. 2011).   
1.7.3 PKA  
PKA is bound in its inactive state until interaction with cAMP. This allows the regulatory 
units to dissociate, leaving the catalytic kinase domain able to bind and phosphorylate its 
targets.  Previous studies have shown that PKA activation in human embryonic kidney cells 
(HEK-293 cells) expressing human SERT (hSERT) causes an increase in SERT basal 
phosphorylation levels (Ramamoorthy et al. 1998).  However there was no change in 5-HT 
transport so the authors concluded that PKA does not have a functional effect on the SERT 
protein. 
1.7.4 PKG 
Previous studies have shown that activation of PKG stimulates 5-HT uptake (Zhu et al. 2004; 
Ramamoorthy et al. 2007).  Whether there is SERT surface re-distribution following PKG 
activation is unclear.  A review of the literature reports that under certain experimental 
conditions and depending on what cell type is used, PKG-mediated SERT regulation and 
trafficking can occur through alternative pathways (Ramamoorthy et al. 2011).  It is possible 
that PKG and p38 MAPK may work together to regulate the function and expression levels of 
SERT at the cell surface.  An increase in 5-HT uptake and SERT cell surface expression is 
observed with PKG or p38 MAPK following stimulation of the adenosine receptor (AR3) at 
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the cell surface in CHO-1 and RBL-2H3 cells (Zhu et al. 2004; Ramamoorthy et al. 2011).  
Inhibition of p38 MAPK prevented the increase in SERT function after AR3 activation, but 
not the increase in SERT surface expression.  This suggests that AR3 stimulates an increase in 
SERT surface expression in a PKG-dependent manner, and increases SERT function in a p38 
MAPK-dependent mechanism (Zhu et al. 2004).  Mutation of a threonine residue in SERT 
expressed in CHO-1 cells abolished PKG-mediated activation of the transporter.  This study 
provided the first identification of a phosphorylation site on SERT and linked it to the 
activation of PKG and subsequent increase in 5-HT uptake (Ramamoorthy et al. 2007). 
  
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:3: Overview of SERT regulation by the major protein kinases.   
Simplified illustration of the most common protein kinases known to regulate SERT cell 
surface expression and function.  Activation of GPCR by 5-HT binding causes changes in 
cAMP levels inside the cell.  This triggers activation of PKA which is known to regulate 
SERT.  Stimulation of GPCR’s also causes cleavage of PIP2 to Dag and IP3, increasing 
intracellular calcium levels.  DAG and calcium trigger PKC activation which is well-known 
regulator of SERT.  Activation of PKC and PKA can activate p38 MAPK which is known to 
regulate SERT expression and function.  In addition, PKG can be activated by increases in 
cGMP which is influenced by p38 MAPK and PKA. 
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1.7.5 Protein Phosphatase 1/2A (PP1/PP2A) 
It appears that inactivation of protein phosphatases reduces transporter activity and down-
regulates surface expression (Vaughan 2004).  In particular, inhibition of protein phosphatase 
1/2A (PP1/PP2A) by okadaic acid leads to a down-regulation of SERT activity.  SERT 
phosphorylation levels are increased which lead to a subsequent decrease in 5-HT uptake.  It 
is suggested that there is a physical association of the PP1/PP2A complex with SERT which 
is regulated by the activity of downstream kinases.  Okadiac acid and PKC activators have 
been shown to disrupt the SERT/PP2A complex, and 5-HT acts as a stabilizing agent 
(Bauman et al. 2000; Vaughan 2004; Jayanthi and Ramamoorthy 2005). 
1.7.6 N-glycosylation 
SERT has been shown to contain two N-glycosylation sites which are implicated in 
maintaining proper protein folding allowing the transporter to be trafficked to and from the 
plasma membrane efficiently (Blakely et al. 1994; Tate and Blakely 1994).  Glycosylation 
does not appear to be essential in regulating transporter function as non-glycosylated mutant 
form of SERT was able to bind and transport 5-HT (Tate and Blakely 1994).  Addition of an 
oligosaccharide (sugar residue) to the transporter begins in the endoplasmic reticulum (ER) 
and is completed in the Golgi apparatus, where the protein can then be directed to the plasma 
membrane for insertion (Sorkina et al. 2003).  SERT is differentially N-glycosylated in the 
brain and in platelets, yet it still proves to be an essential process for maintaining efficient 
protein trafficking and proper protein folding (Blakely et al. 1994).  
1.7.7 Lipid Raft Regulation 
There is evidence to suggest that SERT and the other monoamine transporters, such as DAT 
and NET, are associated with lipid rafts which aid in regulation of these transporters.  Raft-
associated sorting has been linked to several cellular processes including signal transduction, 
protein sorting and membrane trafficking (Chamberlain and Gould 2002).  One study showed 
that SERT is involved in raft-mediated internalization in PKC-mediated regulation (Samuvel 
et al. 2005).  Interestingly this was not shown for p38 MAPK-mediated regulation.  With 
SERT present in lipid rafts, it could be possible that signaling mechanisms specific for lipid 
rafts are affiliated with PKC-mediated down-regulation of SERT (Jayanthi and Ramamoorthy 
2005).   
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1.8 MDMA 
3,4-methylenedioxymethamphetamine (MDMA) is a ring-substituted derivative of 
amphetamines which comprise a subclass of psychostimulants.  It is a stimulant and induces 
hallucinogenic effects on users with feelings of euphoria and heightened perception being 
described (Green et al. 2003; Baumann et al. 2007; Capela et al. 2009; Steinkellner et al. 
2011).  More commonly known as ‘Ecstasy’, it is a drug of abuse popular among young 
people, being used recreationally since the 1980’s especially in the ‘rave’ scene (Green et al. 
2003).  Short-term effects of MDMA include mild depression, hyperthermia, cardiac 
arrhythmia, hypertension, and memory loss (Baumann et al. 2007; Yamauchi et al. 2007). 
Prolonged or chronic use of MDMA is associated with long-term deficits in 5-HT levels and 
loss of 5-HT nerve cell integrity (Wang et al. 2007).  
Amphetamines have a high affinity for the monoamine transporters.  In particular MDMA 
exhibits the highest affinity for the SERT protein, with affinities for the dopamine (DAT) and 
norepinephrine (NET) transporter being tenfold less (Green et al. 2003).  MDMA functions 
as a substrate-type releaser; it binds to SERT, competing for uptake with 5-HT into the nerve 
terminal (Green et al. 2003; Yamauchi et al. 2007; Howell and Kimmel 2008).  Once inside 
the cell, it reverses SERT transport and inhibits uptake of 5-HT from the synaptic cleft, 
thereby causing an initial increase in the extracellular pool of 5-HT (Bengel et al. 1998; 
Green et al. 2003; Sitte and Freissmuth 2010; Steinkellner et al. 2011).  MDMA interferes 
with vesicular storage of 5-HT by competing for uptake by the vesicular monoamine 
transporter (VMAT).  Under physiological conditions, VMAT regulates the concentration of 
intracellular neurotransmitter by retrieving 5-HT from the cytosol into the synaptic vesicles.  
Interference with this regulation leads to more 5-HT being available for non-exocytotic 
release by SERT (Rudnick and Clark 1993; Sitte and Freissmuth 2010).  Monoamine oxidase 
(MAO) rapidly degrades 5-HT that escapes the action of VMAT.  Inhibition of MAO by 
MDMA also contributes to 5-HT being available for SERT-mediated transport into the 
synapse (Sitte and Freissmuth 2010).  In addition MDMA has been shown to inhibit the rate-
limiting enzyme involved in 5-HT synthesis, tryptophan hydroxylase (Schmidt and Taylor 
1987).  The cumulative effects of MDMA are that there is significant rapid efflux of 5-HT 
into the synaptic cleft leading to long-term depletions of 5-HT in the serotonergic system. 
Previous work from our laboratory has shown that MDMA is able to rapidly internalize 
SERT from the cell surface of transfected cell cultures to the intracellular vesicles (Kivell et 
al. 2010).  Additionally no change in SERT mRNA levels was observed in this study which 
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suggests that MDMA targets only SERT function and distribution rather than total SERT 
protein expression (Kivell et al. 2010).   
1.9 Neurotoxicity and Antibody Debate 
It is well-documented that MDMA abuse causes long-term depletion of 5-HT, but there is 
still much discrepancy in the literature about whether the changes in the biochemical markers 
are indicative of neuronal damage or neuronal cell death in humans.  Whether or not MDMA 
is a neurotoxic chemical with the ability to cause nerve cell degeneration, or whether MDMA 
leads to neuroadaptation remains debated throughout the literature.  Early investigators 
labeled MDMA as neurotoxic primarily due to its ability to deplete 5-HT (Battaglia et al. 
1987; Commins et al. 1987; Xie et al. 2006).  This finding lead to speculation over whether 5-
HT deficiency leads to cell death or whether there is a state of neuroadaptation of 5-HT 
metabolism related to SERT trafficking displayed by neurons.  The extent of neurotoxic 
effects is often measured through endpoints thought to be selective for the 5-HT nerve 
terminal.  Tissue 5-HT concentration and SERT levels are commonly used to determine the 
integrity of 5-HT nerve terminals (Wang et al. 2007). 
Subsequent Western blotting experiments were carried out to investigate whether the 
decrease in 5-HT levels following MDMA were due to a loss in SERT protein.  Most of these 
studies report no change in SERT protein levels using anti-SERT antibodies following 
neurotoxic doses of MDMA, even when 5-HT depletion was seen (Rothman et al. 2003; 
Wang et al. 2005; Wang et al. 2007).  However some studies argue that SERT protein density 
and function is decreased after MDMA administration (Battaglia et al. 1987; Xie et al. 2006; 
McLane et al. 2011). This discrepancy in the literature has arisen from the fact that there is a 
large inconsistency and uncertainty over the reported molecular size for SERT, with diverse 
patterns being reported for SERT expression (Xie et al. 2006; Wang et al. 2007; Kivell et al. 
2010).  Previous studies from our laboratory report that there is no change in the 50 kDa 
SERT immunoreative band following MDMA treatment in the rat brain (Kivell et al. 2010).  
In a separate study from another laboratory, an alternative diffuse band was seen at 63-68 
kDa and identified as SERT.  This group has reported that there is a MDMA-induced down-
regulation of this SERT immunoreactive band in rats (Xie et al. 2006; McLane et al. 2011).  
There are a large number of SERT-specific antibodies available; however the specificity of 
these antibodies has been brought into question following these reports.  There has been 
further investigation into whether MDMA is able to alter SERT binding and function without 
affecting SERT protein expression.  A study carried out by Wang et al. (2005) reported that 
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there was no change in SERT distribution between the plasma membrane and cytoplasmic 
fraction.  However due to the questionable specificity of the SERT antibody, these results 
must be viewed with caution.   
Studies from our laboratory used a cellular model where a fluorescent tag was used to 
identify SERT in an attempt to overcome the antibody confusion.  We report that SERT is 
down-regulated from the surface of transfected HEK-293 cells with a corresponding increase 
in the cytoplasmic fraction.  We report no change in mRNA or total SERT protein expression 
which is suggestive that SERT function is affected due to the internalization of the transporter 
after MDMA exposure (Kivell et al. 2010).  These findings from our lab are supported by 
previous studies which show high dosing of MDMA results in a depletion of brain 5-HT and 
reduce SERT binding but does not alter expression of SERT (Wang et al. 2005; Wang et al. 
2007).  Similarly a previous study reported a loss in SERT surface signal intensity following 
MDMA treatment which is in support of our published findings (Kittler et al. 2010; Kivell et 
al. 2010).  
In regards to the neurotoxic status of MDMA, research employing more sensitive and 
detailed techniques has been used in an attempt to determine the degree of neurotoxicity of 
MDMA. Various staining techniques and identification of common neurotoxic markers to 
investigate 5-HT deficiency and whether it leads to cell death have been reported on, and 
reviewed in recent literature (Green et al. 2003; Baumann et al. 2007; Steinkellner et al. 
2011).   
Silver staining is a sensitive indicator of damage caused by neurotoxic chemicals and is used 
to identify neuronal degeneration.  It has been used to show that MDMA administration 
causes degeneration in nerve terminals, axons and cell bodies throughout the rat brain 
(Commins et al. 1987).  However it must be noted that the pattern of degeneration observed 
by the stain did not correlate with the distribution of serotonergic neurons, indicating that 
only non-specific neuronal damage occurred rather than specific serotonergic cell death 
(reviewed by Baumann et al. 2007).  The high-dosing regime used for MDMA administration 
(>25 mg/kg) is excessive and therefore unlikely to be physiologically relevant to humans.   
  Similarly, non-specific neuronal degeneration after MDMA administration was observed 
using another novel histological stain, Fluoro-Jade B.  This is an anionic fluorescin derivative 
that selectively stains for degenerating terminals, axons and cell bodies.  Rats that were 
administered MDMA doses over 20 mg/kg had detectable neural degeneration, however cells 
20 
 
identified as damaged were not specifically serotonergic, and did not overlap the pattern of 5-
HT deficits (Schmued and Xu 2003; Baumann et al. 2007).  Another factor noted in the study 
carried out by Schmued et al. (2003) was that neuronal degeneration was only observed in 
rats that displayed hyperthermia (temperatures >41ºC).  In rats that did not experience 
hyperthermia, no degeneration was seen; as detected by Fluoro-Jade B.  This is suggestive of 
a link between elevated body temperatures and adverse effects of MDMA (Schmued and Xu 
2003; Baumann et al. 2007).  MDMA neurotoxicity is predominantly investigated in rats that 
are exposed to MDMA doses of 10 mg/kg or higher, whether as single or repeated injections.  
The debate of the neurotoxic potential of MDMA partially remains due to the disagreement 
over the interspecies scaling equation.  Extrapolating data from animal models to humans 
about the relevance of MDMA doses is a point of controversy due to the validity and 
limitations of the equation.  5-HT depletions seen in rats occurs after MDMA doses of 10-20 
mg/kg, whereas human recreational doses are between 1-3 mg/kg, with users taking an 
average of two ecstasy tablets at one time (Baumann et al. 2007; Steinkellner et al. 2011).  
With rats, at the this high level of dosing it has been observed that significant hyperthermia 
occurs which can exacerbate 5-HT depletions, causing incorrect, or over-exaggerated 
conclusions about MDMA neurotoxicity (Baumann et al. 2007).  MDMA-induced 
neurotoxicity and the link to the hyperthermic response still needs to be further investigated 
to establish the relationship they have on the serotonergic system.  Other variables that affect 
MDMA response range from dose, species, ambient and body temperatures, as well as route 
of administration (Bai et al. 2001; Wang et al. 2005). 
Glial fibrillary acidic protein (GFAP) is a glial-specific structural protein and its expression 
levels are used as a neurotoxic CNS marker.  When neurons are damaged or killed, glial cells 
replicate to take over the space left behind.  An increase in GFAP expression is indicative of 
the neurotoxicity state of the CNS.  A study carried out by O’Callaghan et al. (1993) 
observed that when rats were administered 10-30 mg/kg MDMA, they were unable to induce 
an increase in GFAP expression, even though a depletion in 5-HT was seen throughout the 
brain.  A separate group of rats from the same study were administered a higher MDMA dose 
at 75-150 mg/kg, observed an increase in GFAP expression in various brain regions, but 
which did not, however, correlate with the degree of 5-HT depletion (O'Callaghan and Miller 
1993).   5,7-dihydroxytryptamine (5,7-DHT), a 5-HT neurotoxin, was used to compare GFAP 
expression levels.  At doses which caused comparable 5-HT depletions as MDMA, only 5,7-
DHT was able to induce GFAP expression (O'Callaghan and Miller 1993; Baumann et al. 
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2007).  Recent studies also show that MDMA failed to have an effect on measures of reactive 
gliosis as indicated by the lack of change in immunoreactive GFAP (Bai et al. 2001; Pubill et 
al. 2003; Baumann et al. 2007).  However, in contrast to these studies, there has been findings 
published which report that MDMA is able to enhance histochemical staining for GFAP 
(Aguirre et al. 1999).  The explanation for the discrepancies between the literatures is not 
clear; differences in experimental protocols may have a significant effect on the outcome of 
the findings for each study.  Aguirre et al. (1999) administered a dosing regimen of a single 
injection of 20 mg/kg of MDMA, whereas Pubill et al. (2003) used multiple injections of 20 
mg/kg over a course of four days.  Variation between the different rat strains, as well as the 
different brain regions examined could all impact on the observed neurotoxic effects of 
MDMA.   
The majority of data in the literature that states MDMA causes a significant depletion in 5-
HT levels (whether it from a single or repeated doses), cannot reliably induce silver positive 
staining or markers of reactive gliosis.  Wang et al. (2007) demonstrate that high-dose 
MDMA treatment which was able to reduce SERT binding by 90% left a significant number 
of functionally intact 5-HT nerve terminals.  Interestingly they showed that MDMA-induced 
5-HT depletion in rats could have 5-HT levels restored by the administration of the 5-HT 
precursor L-5-hydroxytryptophan (Wang et al. 2007).  This suggests that MDMA effects 
were not neurotoxic, but demonstrated neuroadaptation to the drug.  The extent of MDMA-
induced decreases in SERT binding appears to be dependent on in vitro assay conditions.  
Until a consensus can be reached about the extent that MDMA induces neurotoxicity, it must 
be kept in mind that MDMA-induced 5-HT depletions may be due to persistent adaptive 
changes in protein expression and/or function.  
1.10 MDMA-induced regulation of SERT 
The mechanism by which MDMA is able to modulate SERT function and redistribution is 
unclear.  PKC is an important regulator of SERT, and a plausible hypothesis is that PKC 
activation in the pre-synaptic terminal occurs in response to MDMA binding to SERT.  
MDMA binding to SERT is known to cause an increased influx of intracellular calcium 
(Kramer et al. 1997).  An extended period of elevated intracellular calcium levels is necessary 
for the translocation and association of PKC to the neuronal membrane.  It is an important 
cofactor for the binding of PKC to biological membranes under basal conditions (Kramer et 
al. 1998).  Previous studies carried out in rat synaptosomes have shown that MDMA is 
unable to induce PKC translocation when synaptosomes are incubated in Ca
2+
-free 
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conditions.  This is surprising when taking into the account the Ca
2+
-independent mechanism 
of MDMA-induced 5-HT release.  The exact mechanism of calcium entry into the cell by 
MDMA is not known (Kramer et al. 1998).  In the same study it was also demonstrated that 
animals pre-treated with fluoxetine before MDMA treatment were unable to stimulate PKC 
translocation.  Fluoxetine may inhibit PKC activation by competing with MDMA for SERT 
binding (Kramer et al. 1998).  Prolonged activation of PKC has been implicated in several 
calcium-dependent neurodegenerative processes, and so its role in MDMA-induced 
neurotoxicity is of interest.  It is suggested that long periods of PKC activation can lead to 
changes in the homeostatic function of 5-HT neurons, which could modulate local 
mechanisms in the nerve terminal increasing the cells susceptibility to damage by MDMA 
(Kramer et al. 1998).  Whether amphetamines such as MDMA have an effect on SERT 
through a PKC-dependent mechanism is unknown, however studies conducted on the 
dopamine transporter (DAT) have shown that amphetamines can increase striatal PKC 
activity in rat synaptosomes (Giambalvo 1992; Giambalvo 1992).  The mechanism behind the 
increases in PKC activity due to amphetamine treatment is still unclear.  It was shown that 
the presence of intracellular calcium is essential for the amphetamine-mediated stimulation of 
PKC activity in the dopaminergic system.  Rat synaptosomes treated with a calcium chelator 
showed that a depletion of intracellular calcium resulted in the attenuation of dopamine 
release induced by amphetamine treatment (Giambalvo 2003).  In the serotonergic and 
dopamernergic systems the mechanism for the requirement of intracellular calcium is as yet 
unknown.  Calcium plays an important role in the functioning of modulators such as 
calmodulin and calmodulin-dependent protein kinase II, which could indirectly alter PKC 
activity. 
1.11 Summary 
SERT down-regulation is controlled through a multitude of signaling networks present in the 
cell.  These networks are made up of pathways which interlink and regulate one another, 
some of which are constitutively in place, while others are activated upon extracellular 
signals.  For example, three major kinases, PKC, PKA and p38 MAPK are activated via 
separate pathways, yet act to regulate one another.   This makes them responsible for SERT’s 
phosphorylation state which dictates the rate of SERT insertion into the membrane, SERT 
function and SERT trafficking inside the cell.  The specific residues responsible for 
regulation of SERT by molecules such as kinases are not completely understood.  It appears 
that basal phosphorylation occurs at separate sites to those responsible for rapid regulation of 
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SERT.  How MDMA interacts and affects the signaling networks responsible for SERT 
regulation is unclear.  One possible hypothesis that is explored in this study is whether 
MDMA is able to target PKC, thereby activating it and causing down-regulation of SERT. 
1.12 Significance 
Despite more than two decades of research, the mechanisms by which MDMA is able to exert 
its effect on the serotonergic system remains to be fully elucidated.  Being able to determine 
the biochemical pathways that are affected by MDMA in the neuronal cell will help to fill a 
gap in knowledge about how MDMA regulates SERT.  Further information will help identify 
if the effects of MDMA are reversible or preventable.  When working in animal or cell 
models, limitations arise in SERT protein research due to the lack of accurate and specific 
antibodies to the SERT protein.  This study attempts to use a cell model expressing human 
SERT (hSERT) tagged with green fluorescent protein (GFP) to overcome this limitation and 
confidently investigate MDMA-induced effects.  Research into this field will help bridge the 
gap in the information that is currently available on the cellular effects of MDMA. 
1.13 Aims and Objectives: 
The overall aim of this study was to investigate whether MDMA exerted its regulatory effect 
on SERT function and cell surface expression through a PKC-dependent pathway.  The 
specific objectives of this study were:  
1) Evaluate two commercially available antibodies targeting SERT to validate antibody 
specificity,  
2) Determine the effects of MDMA on cell-surface SERT expression and function,  
3) Identify the cellular signaling mechanism of how MDMA regulates SERT by investigating 
the effects of PKC, a known regulator of SERT function.  
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2 Chapter 2: Materials and Methods 
2.1 Tissue Culture 
Cell lines used in this study were grown and maintained under PC2 conditions in the School 
of Biological Sciences, Victoria University of Wellington.  All cell work was carried out in a 
class II biological safety cabinet (AES Environment Pty LTD, Auburn, Australia) with HEPE 
air filters.  Before use, sterilization with Ultraviolet (UV) light (1390 mW/m
2
) for 15 min was 
carried out and all surfaces were wiped down with 70% ethanol.  Cells stocks were grown in 
a Heracell incubator (Kendro Laboratory Products, GmbH, Germany) in a humid 
environment kept at 37ºC and supplemented with 5% CO2.  Sterile plastic-ware used to carry 
out experiments was purchased from BD Biosciences and Greiner Bio One.  Two different 
cell lines were used in this study: human embryonic kidney cells (HEK-293) and mouse 
neuroblastoma cells (N2A).  Both cell lines were purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA) and were used between passage number seven and 
one hundred. 
2.1.1 Cell Lines 
2.1.1.1 Human embryonic kidney cells (HEK-293) 
Transformed with adenovirus 5, HEK-293 cells are an immortalized cell line derived from 
human embryonic kidney cells.  They were maintained in Dulbeccos modified Eagle medium 
(DMEM) (Gibco, Invitrogen, Auckland, NZ) containing 10% fetal calf serum (FCS, ICP 
biologicals, Auckland, NZ)), 1% Penstrep antibiotic (Penicillin G sodium 5000 units/mL. 
Streptomycin sulphate 5000 units/mL in 0.85% saline, Gibco, Invitrogen) and 200 µM L-
glutamine (Gibco, Invitrogen).  DMEM media containing no penstrep antibiotic (containing 
200 µM L-glutamine and 10% FCS) was used for cell transfection experiments.  For confocal 
microscopy and biotinylation experiments, 1 mL of cells were plated at a density of 
1x10
6
/mL in 35 mm dishes.  Western blotting and rotating disc voltammetry experiments 
required 2 mL of cells to be plated out at a density of 1x10
6
/mL in 60 mm dishes.  In addition 
rotating disc electrode voltammetry used 7 mL of cells plated out at density of 1x10
6
/mL in 
100 mm dishes. 
2.1.1.2 Mouse neuroblastoma cells (N2A) 
Originating from Mus musculus, N2A cells are adherent mouse brain neuroblastoma cells.  
They were maintained and cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium containing 10% FCS and 1% Penstrep antibiotic.  RPMI medium containing no 
Penstrep (supplemented only with 10% FCS) was used for cell transfection experiments.  
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Cells were plated out at a density described for HEK-293 cells for Western blotting, 
biotinylation, confocal microscopy and rotating disc electrode voltammetry experiments. 
2.1.2 Cell growth and passaging 
Cryovials of cell stocks were stored in a liquid nitrogen dewar and thawed in a 37ºC water 
bath for use in experiments.  Defrosted cells were transferred to 75 mL flasks fitted with MIT 
filter screw caps (Greiner bio-one, Raylab, Auckland, NZ) containing 7 mL of culture 
medium and 1% Penstrep.  24 hours later, the culture medium was removed and replaced 
with fresh growth medium.  
Cells were passaged into 250 mL flasks when 80% confluency was reached.  Cells were 
washed with sterile phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 8.1 mM 
Na2HPO4, 1.5 mM KH2PO4, pH 7.4) before a 5 min incubation with 1 mL of TrpLE Express 
(Gibco, Invitrogen).  Gentle mechanical agitation of the flask helped to detach cells which 
were then centrifuged at 300 g for 5 min.  The concentration of the pelleted cells was 
determined using a haemocytometer to count an aliquot of cells diluted in 0.4% tryphan blue 
(Sigma). The cells were then diluted 1:4 and reseeded in two separate 250 mL flasks; one to 
carry on the cell line, the other to be used to freeze down and replace stocks removed from 
the liquid nitrogen.  1 mL aliquots of log phase cells were frozen in liquid nitrogen at a 
concentration of 1x10
6
 cells/mL in their appropriate culture medium containing 10% 
dimethyl sulfoxide (DMSO). 
2.1.3 Cell transfection 
On day 1 cells were plated into dishes at a density respective of the experiment planned.  On 
day 2, cells were transfected with the GFP-hSERT plasmid when growth reached 60-70% 
confluency.  Lipofectamine 2000 reagent (Invitrogen) and Optimum I medium (Invitrogen) 
were used to create the transfection mixture.  For HEK-293 cells, 3 µL of Lipofectamine 
2000 was made up to 50 µL of Optimem I per 1x10
6
 cells, and incubated for 5 min at room 
temperature.  In a separate tube, GFP-hSERT plasmid DNA (kindly donated by S. 
Ramamoorthy) was made up to 50 µL with Optimem I per 1x10
6
 cells to a final concentration 
of 0.5 µg/mL.  After an initial 5 min incubation, the two separate mixtures were added 
together and incubated for a further 20 min.  Dishes containing the cells to be transfected had 
old culture medium replaced with fresh penstrep-free medium and 100 µL per 1x10
6
 cells of 
the transfection mixture was added.  Cells were used 48 hours after transfections.  For N2A 
cells, 4 µL of Lipofectamine 2000 and 1 µg/mL of GFP-hSERT per 1x10
6
 cells were used. 
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2.2 Plasmid Preparation 
2.2.1 Luria Broth (LB) kanamycin agar plates 
LB-broth (10 g/L NaCl, 5 g/L Yeast extract, 10 g/L Bactotryptone) (Appendix) and LB-Agar 
(10 g/L NaCl, 5 g/L Yeast extract, 10 g/L Yeast agar, 10 g/L Bactotryptone) (Appendix) were 
autoclaved at 121ºC at 20 1b/in
2
 for 20 min to sterilize.  Once cooled, a final concentration of 
50 µg/mL of kanamycin antibiotic was added.  Agar plates were poured, left to set and stored 
at 4ºC until needed. 
2.2.2 Transformation of MAX Efficiency® DH5αTM Competent Cells 
100 µL aliquots of MAX Efficiency® DH5αTM Competent Cells (Invitrogen) were thawed on 
ice and divided into 50 µL aliquots in microcentrigfuge tubes.  One aliquot served as a 
negative control, while the other had 20 ng of GFP-hSERT plasmid DNA added to it.  Cells 
were incubated on ice for 1 hour, and then heat shocked at 42ºC for 2 min in a heat block 
(Global Science).  The tubes were then transferred to ice for a further 5 min.  450 µL of SOC 
medium (Invitrogen) was added to each tube and left to shake at 225 rpm for 1 hour in a 37ºC 
shaker (Bioline, Edwards Instrument Company, Australia).  A ‘lawn’ culture was then 
created by spreading 100 µL of each mixture on LB-agar plates containing antibiotic and left 
to incubate overnight at 37ºC in a humid incubator. 
2.2.3 Cultivation of Escherichia coli (E.coli) 
From the previously described ‘lawn’ culture, single colonies of transformed DH5α cells 
were streaked out onto new LB-agar plates containing antibiotic and incubated overnight at 
37ºC.  The negative control described previously was used as a reference to ensure that this 
procedure was only carried out if no growth was generated with the non-transformed bacteria.  
Growth would indicate a contamination of the bacterial stock, and a new transformation 
would have to be carried out.  The following day, a single colony was picked from the plate 
using a sterile pipette tip and resuspended in 2 mL of LB-broth containing antibiotic to create 
an overnight culture.  12-18 hours at 37ºC with shaking at 225 rpm, 200 µL of the overnight 
culture was added to 200 mL of LB-broth containing antibiotic.  This culture was incubated 
overnight in the same conditions, and the following day a plasmid purification was carried 
out (see Section 2.2.4). 
2.2.4 Plasmid purification using the Qiagen hiSpeed Maxi Kit 
GFP-hSERT plasmid DNA was extracted from the 200 mL bacterial culture following the 
manufacturer’s protocol for the Qiagen hiSpeed Maxi kit (Biolab, Auckland, NZ). 
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Briefly, the 200 mL culture was centrifuged at 6000 g for 25 min at 4ºC in a Sorvall 
Evolution RC centrifuge (Kendro Laboratory Products, Bath, UK) and the supernatant 
removed. The bacterial pellet was resuspended in 10 mL of resuspension buffer containing 
RNase A (Buffer P1).  Following this, 10 mL of Lysis buffer (Buffer P2) was added and 
mixed by inverting solution 4-6 times.  After a 5 min incubation at room temperature, 10 mL 
of chilled neutralization buffer (Buffer P3) was added to halt the lysis reaction.  The lysate 
was transferred to a QIAfilter Cartridge and incubated for 10 min at room temperature.  A 
HiSpeed Maxi Tip was equilibrated by placing it over a waste container allowing 10 mL of 
Buffer QBT to flow through the filter.  The lysate was filtered through the QIAfilter 
Cartridge into the HiSpeed Maxi Tip so the DNA binds to the filter resin.  The tip containing 
the DNA was then washed with 60 mL of a wash buffer (Buffer QC), and the DNA eluted 
into a sterile 50 mL Falcon tube using Buffer QF.  The resulting DNA was precipitated using 
10.5 mL of molecular grade isopropanol (Sigma) for 5 min.  A 30 mL syringe attached to a 
QIAprecipitator Maxi Module was used to filter the isopropanol mixture, allowing the 
precipitator to capture the DNA strands. 2 mL of 70% ethanol (Ajax Chemicals, Auckland, 
NZ) was used to wash the DNA strands.  Air was rapidly pushed through the syringe twice in 
order to air dry the filter to prevent any ethanol carry-over in the final DNA plasmid solution.  
A 5 mL syringe was then attached to the precipitator containing the DNA and placed over a 
sterile microcentrifuge tube.  500 µL of endotoxin free buffer (Buffer TE) was added and 
allowed to run through the filter, eluting the DNA to be collected in the tube.  The eluted 
DNA was transferred back to the syringe the process was repeated a second time to ensure all 
DNA from the precipitator was collected.  
The concentration and purity of the plasmid DNA was determined using a Nanodrop ND-
1000 spectrophotometer (Biolab, Auckland, NZ).  Ultrapure MilliQ water (Barnstead 
Easypure II, MA, USA) was used to initialize and blank the machine.  1 µL of plasmid DNA 
sample was then placed on the sensor and a recording was measured using the package 
software (ND-100 v3.1.0).  DNA yields over 250 ng/µL were deemed acceptable for use in 
transfection experiments.  The purity measurement obtained from the absorbance A260/A280 
ratio was between 1.6 - 2.0 for transfection experiments. 
Transformed bacterial cultures (2 mL) were frozen at -80 ºC in 500 µL aliquots in 20% 
glycerol for transformed bacterial stocks.  Keeping stocks of adequate transformed bacteria 
meant that future plasmid purifications were able to be carried out without transforming 
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further DH5α cells.  Instead scrapings could be made from the transformed bacterial stocks 
and streaked onto LB-agar plates containing antibiotic to create single colonies. 
2.3 Western Blotting 
2.3.1 Protein lysate preparation 
For the antibody specificity experiments Western blotting techniques were carried out.  
Firstly the two different cell lines, HEK-293 and N2A, were plated and transfected as 
described previously (Section 2.1.1).  HEK-293 cells were transfected over a range of 0.2-1 
µg of GFP-hSERT plasmid DNA.  Similarly N2A cells were transfected over a range of 1 µg 
- 4 µg plasmid DNA.  Non-transfected cells were run alongside each experiment for 
comparison in the Western blots.  Protein was extracted from the cells by removal of the 
culture medium and replacing with 400 µL of TrpLE Express to detach cells from the dishes. 
After gentle tapping, the liquid was transferred to a 1.5 mL sterile microcentrifuge tube and 
centrifuged at 300 g for 5 min at room temperature (Eppendorf 5415R, Global Science, NZ).  
The pellet was resuspended in Radioimmuno-precipitation assay (RIPA) buffer (10 mM Tris-
HCL, 150 mM NaCl, 1 mM EDTA, 1% Triton-X-100, 0.1% SDS, 1% sodium deoxycholate, 
pH 7.5 (Appendix)) containing 10 µL/mL of protease inhibitor to lyse the cells,  with final 
volumes 180, 300 and 400 µL being used. Cells were left to lyse in a rotating Labquake 
machine at 4ºC for 1 hour. The DNA pellet was sucked out using a sterile pipette and 
discarded.  The remaining whole protein lysate concentration was then quantified using a 
BCA protein assay (Pierce IL) as per the manufacturer’s protocol.  Briefly BCA protein 
standards were diluted to give a concentration range of 0.025-1.0 mg/mL, so that a standard 
curve of the absorbances could be generated to determine the protein concentration of the 
lysate samples.  Using the linear portion of the standard curve, the protein concentration of 
the whole cell lysates was able to be determined.  The samples were then diluted so that a 
range of protein concentrations ranging from 2.5-75 µg could be loaded onto a SDS-
polyacrylamide gel.   
2.3.2 SDS polyacrylamide gel electrophoresis and transfer of protein to PVDF 
Membrane 
Protein  lysates were diluted using RIPA buffer to desired concentration, 50 µL aliquots were 
mixed with 15 µL of 5x reducing buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 20% glycerol, 
1% bromophenol blue (Appendix)) containing 10% β-mercaptoethanol (Sigma).  20 µL of 
each protein sample was loaded onto 10- or 15-well SDS-PAGE gels consisting of a 10% 
separating gel and 4% stacking gel (Appendix).  1 µL of Precision Plus Protein Standard 
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Dual Colour Molecular Weight Marker (Biorad, CA, USA) was loaded onto each gel to serve 
as a ladder for determining band sizes.  The protein lysates were separated out on the SDS-
PAGE gels by electrophoresis for 90 min at 120 V in 1x running buffer (3.5 mM SDS, 25 
mM Tris base, 190 mM glycine.  Prior to Western blotting gels were scanned on a Fuji film 
laser scanner (Fujifilm FLA-5100, Tokoyo, Japan) using a 473 nm laser and BPB1 filter set 
at 800 V, allowing visualization of GFP-hSERT which also serves as a loading control. 
Following scanning, the gels were used for a Western Blot transfer.  The proteins in the gel 
were transferred to a polyvinylidine difluoride (PVDF) (0.2 µM pore size, Millipore 
Corporation, MA) membrane.  The membrane was hydrated by pre-soaking in methanol for 5 
min, then in western transfer buffer before being placed in the Western blotting cassette. The 
transfer cassette was arranged so that the black side of the cassette faced the back, followed 
by the sponge, 3 MM filter paper, SDS-gel, membrane, followed by another piece of 3 MM 
filter paper, and sponge.  The cassette was then inserted into the Bio-Rad Tetracell transfer 
set (Biorad) containing an ice-pack, and immersed in Western Transfer buffer (25 mM Tris, 
0.2 M glycine, 20% methanol, 1% SDS.  The transfer was run at 4ºC for 17 hours at 20V. 
2.3.3 Probing for the protein of interest: GFP-hSERT 
Following disassembly of the transfer cassette; the membranes were rinsed in Tris buffered 
saline (TBS, 50 mM Tris base, 150 mM NaCl, pH 7.5 and blocked for one hour in the 
appropriate blocking solution (described in Table 2.1) at room temperature with gentle 
rocking.  Following the blocking reaction, membranes were incubated with the primary 
antibody diluted in appropriate blocking buffer (described in Table 2.1) overnight at 4ºC with 
constant shaking.  The two primary antibodies investigated were either directed at the N 
terminal or the C terminal of the SERT protein.  Antibody 1 is from Santa Cruz and is raised 
against the C terminal and Antibody 2 from Sigma Aldrich and targets the N terminal (aa 1-
20).  After incubation with the primary antibody, membranes were rinsed with 3 mL of TBS 
containing 0.1% Tween 20 (T-TBS) 3 times.  They were then further incubated with 3 mL of 
T-TBS for 5 min intervals 3 times.  The corresponding secondary antibody (described in 
Table 2.1) was diluted in T-TBS and added to membranes and incubated for 1 hour in the 
dark at room temperature with constant shaking.  Detection of the Cy5 tagged secondary 
antibody was visualized using the Fuji laser scanner using a 635 nm laser at 400 V with the 
DBR1 filter.  ImageJ software was used to investigate the pictures of the scanned membrane. 
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Table 2:1: List of Antibodies used in Western blotting experiments   
 Protein of 
Interest 
Blocking 
Agent 
Primary Ab Dilution Secondary Ab Dilution 
Antibody 1 hSERT 5% donkey 
serum in 
TTBS 
Goat polyclonal to C 
terminal  
(Santa Cruz) 
1:500 
1:1000 
 
Dylite anti-
mouse Cy5 
 
1:2500 
Antibody 2 hSERT 5% milk 
powder in 
TTBS 
 
Rabbit polyclonal to 
N terminal (aa1-20) 
(Sigma Aldrich) 
 
1:1000 
 
Goat anti-
rabbit Cy5 
(GE 
Healthcare) 
 
1:3000 
2.4 Cell surface biotinylation 
HEK-293 and N2A cells were plated and transfected as described previously in section 2.1.1 
and biotinylation experiments were carried out 48 hours after transfection.  Methods used 
have been previously described (Bolan et al. 2007; Zapata et al. 2007). 
β-PMA, MDMA, and ionomycin were dissolved in 1 x PBS (1.4 M NaCl, 26.8 mM KCl, 
81.0 mM Na2HPO4, 14.7 mM KH2PO4, pH7.4) so that final concentrations of 1 µM β-PMA, 
10 µg/µL MDMA and 5 µM ionomycin were added to 1 mL culture dishes. The inhibitor 
compound Bisindolylmaleimide I (Bis I) was dissolved in DMSO so that a final 
concentration of 200 nM was added to the 1 mL cell culture dishes.  The compounds were 
added for the required amount of time for maximal effect to occur to investigate the effects 
they have on SERT expression.  Cells were then washed twice with ice-cold PBS/Ca-Mg 
(PBS containing 0.1 mM CaCl2 and 1 mM MgCl2, pH 8.0) and incubated with EZ link NHS-
Sulfo-SS-biotin (Pierce) in PBS/Ca-Mg at a concentration of 1 mg/ml for 30 min at a 
temperature of 4ºC in the dark with gentle shaking.  Cells were washed 2 x times and 
quenched by addition of 100 mM glycine in PBS/Ca-Mg.  This was carried out in the dark at 
temperature of 4ºC for 20 min with gentle shaking.  Lysing of the cells was achieved by 
addition of 400 µL of RIPA buffer containing 10 µL/mL of protease inhibitor (Sigma) and 
incubated for 1 hour at 4ºC with constant shaking.  Lysate samples were then transferred to 
sterile microcentrifuge tubes and centrifuged at 16,000 g in a bench top centrifuge 
(Eppendorf, Eppendorf South Pacific, Australia) for 30 min at 4ºC.  The resulting DNA pellet 
was discarded and a 50 µL sample of the supernatant was collected and stored on ice as 
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representative of the total protein fraction.  400 µL of the supernatant was then incubated 
with 100 µL of streptavidin beads (Pierce) in filter columns.  These were incubated with 
gentle mixing in a rotating Labquake machine for 1 hour in the dark.  Plugs were removed 
from the columns and centrifuged at 500 g for 1 min at 4ºC, and the liquid spun down into the 
collecting tube. 50 µL samples representing the intracellular fraction were stored on ice in the 
dark until needed.  The beads were then washed by passing 400 µL of RIPA buffer through 
the columns 3 x times, with centrifugation at 16,000 g for 1 min at 4 ºC being carried out 
after each wash.  Elution of the bound proteins from the beads was carried out by incubation 
with 40 µL of 5x reducing buffer (Appendix 1: Solutions) containing 10% β-mercaptoethanol 
for 30 min at room temperature in the rotating Labquake machine.  A final centrifugation spin 
was carried out at 500 g for 1 min at 4ºC to collect the sample which contains the cell surface 
fraction.  To the total and intracellular fractions, 15 µL of 5 x reducing buffer containing 10% 
β-mercaptoethanol was added.  The fractions were then analyzed by loading 20 µL of each 
sample onto a 10% SDS-PAGE gels and electrophoresis was carried out for 90 minutes at 
120 V.  Gels were transferred onto Western blotting membranes as described in section 2.3.2.  
Using Western blotting techniques, HEK-293 and N2A cells were probed for GAPDH 
(1:1000, Abcam) and actin (1:1000, Abcam) respectively for 1 hr at room temperature.  
GAPDH and actin are two common housekeeping proteins which are expressed only in the 
intracellular fraction in the respective cell lines.  GAPDH and actin therefore serve as internal 
references to ensure the cells were not lysed before the addition of biotin, validating the 
specific localization of SERT. 
SERT expression was measured by the densitometry of the band size identified as GFP-
hSERT prior to Western transfer using a laser gel scanner at 473 nm.  Using Image-J 
software, the integrated density of each band was determined following subtraction of 
background readings.  The background corrected cell surface and intracellular readings were 
then normalized to the total fractions for each corresponding treatment.  For each treatment, 
the normalized cell surface and intracellular data were also normalized to the matching 
vehicle-treated samples in each gel.   This allowed for between-gel comparisons to be made. 
Graphpad prism 4 software (GraphPad Software Inc, La Jolla, CA, USA) was used to graph 
the values and one-way ANOVA, followed by Bonferroni post tests, was conducted to test 
for significance between treatments. GAPDH and actin immunoblots were identified through 
detection of the Cy5 tagged secondary antibody using the Fuji laser scanner as described in 
Section 2.3.3. 
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2.5 Total Internal Reflection Fluorescence Microscopy (TIRFM) 
TIRFM experiments followed the protocol described in Furman et al. (Furman et al. 2009).  
HEK-293 and N2A cells were plated and transfected as described previously for confocal 
microscopy in 35 mm glass-bottomed petri dishes coated with 0.5 mg/mL poly-d lysine.  All 
experiments were performed 48 hours following transfection.  TIRFM monitoring and 
imaging was carried out using an Olympus Flv1000 confocal laser scanning microscope 
equipped with a QImaging Digital Camera 6.2.0.6 (QImaging ROLERA-MGI Fast1394; 
Surrey, BC, Canada).  All experiments were performed at 37ºC.  The microscope stage 
incubator (INU-21LCS-F1 model, Tokai Hit Co., Ltd, Japan) was equilibrated with a flow of 
carbogen (95% O2, 5% CO2) to maintain the optimal pH.  A 300 µL syringe was used to 
dispense the compound that was being tested directly into the dish containing the transfected 
cells though the inlet port of the chamber.  Cells were left to equilibrate in the chamber for a 
minimum of 20 minutes before experimentation started.  Using the 100 x objective lens 
(Olympus, PLAPO 100x, OTIFM, NA 1.45) a region of mono-layer cells were chosen and 
focused on using FITC epi-florescence, the TIRFM camera and  Image Pro Plus 7.0 
acquisition software (MediaCybernetics, Bethesdus, MD, USA).  TIRFM settings were used 
so that the microscope scanned a penetration depth of 100 nm, a FS of 11 nm and a refractive 
index of the sample was 1.45.  The microscope was set so that the focal plane focused on the 
part of the cell membrane that was adhered to the glass bottom of the dish.  Cells were chosen 
so that a range of GFP-expression levels could be imaged, but could still clearly be seen at 
laser power settings ranging from 0.5-1.2% (473 nm laser, GFP filter).  The camera 
(QImaging Digital Camera 6.2.0.6) was set to an acquisition area of 512 x 512 pixels with a 
capture depth of 14 bit mono (16 bit image class) and an exposure preview of 00.902.508 s 
with a capture exposure time of 3 s using Image Pro Plus Sotfware. 
For the longer time course experiments (40 min), the first image captured was time 0, and 
subsequent images were captured every minute for the duration of the time course.  The first 
10 frames (10 min) were used as a baseline.  Following this either MDMA (final 
concentration 10 µg/mL) or β-PMA (final concentration 1 µM) was delivered into the dish 
using a syringe.  To ensure no photo-bleaching of the cells occurred, the laser was blocked 
from the sample between scans.  Controls were carried out to test for photo-bleaching and 
conditions set to ensure photo-beaching were not seen.  In short-time experiment courses (up 
to 10 min) images were set to capture every 5 seconds for a total of 70 frames.  After capture 
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of the first 10 baseline images, either MDMA or the control compound was delivered through 
the syringe. 
Images collected were analysed using Image-J software. Each individual cell was selected 
around and the mean fluorescence intensity determined.  This was done for each image frame 
of the scan.  Each reading was normalized back to the first reading after the baseline period 
(arbitrary fluorescent unit = 1) and the subsequent normalized pixel intensities were graphed 
in GraphPad Prism.  Statistical analysis using two-way ANOVA, with Bonferroni post test, 
was applied to test for significance between treatments. 
2.6 Rotating disc electrode voltammetry (RDEV) 
Rotating disc electrode voltammetry (RDEV) is an electrochemical technique that has been 
previously used for the measurement of real time 5-HT uptake and release in tissue samples 
such as whole brain rat synaptosomes (Hagan et al. 2010).  Here, RDEV is used to investigate 
the changes in SERT function as defined by rate of change of 5-HT uptake under different 
treatments in HEK-293 and N2A cells.  A rotating glassy carbon electrode (Pine Instruments, 
special order AFMDO3GC, Pennsylvania) is connected to a high-precision MSR rotator 
(Pine Instruments) and set to spin at 2000 rpm which keeps the cell sample or buffer in the 
custom glass chamber mixed.  Rotation rates were recorded and maintained by a digital laser 
tachometer.  Connected to the glass chamber an Ag/AgCl reference electrode was used to 
apply a +450 mV potential relative to the electrode by an eDAQ potentiostat EA161 (eDAQ, 
NSW, Australia) and a platinum wire was used as an auxiliary electrode.  A PC computer 
with Chart software (eDAQ, NSW, Australia) was used to save the resulting currents 
recorded by an eDAQ recorder 210 (eDAQ, NSW, Australia).   
2.6.1 Standard curve 
Concentration response curves were created each day prior to performing experiments.  
Serotonin stock was diluted into KREB buffer (130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 
1.2 mM MgSO4.6H2O, 1.2 mM KH2PO4, 10 mM HEPES, 10 mM D-glucose, pH 7.4) was 
used to give 5-HT concentrations of 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0 and 5.0 µM.  A linear 
regression was generated by calculating the increase in current (nA) at each 5-HT 
concentration, so that data collected from the cell samples can be transformed into µM based 
on the measured nA values.   
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2.6.2 Preparation of GFP-hSERT transfected HEK-293 and N2A cells for RDEV 
Cells transfected with GFP-hSERT were treated with compounds so that their maximal effect 
on SERT was achieved, then washed 5 x times with 37ºC KREBs buffer saturated with 
5%CO2/95%O2.  They were harvested by mechanical agitation with the KREBs buffer and 
centrifuged at 300 g for 5 min.  The pellet of cells were then resuspended in either 1.2 mL or 
300 µL (depending on size of the dish, 100 mm and 60 mm respectively) of KREBs buffer 
saturated with carbogen (5%CO2/95%O2) and maintained at 37ºC for up to 20 min until 
needed. 
For 5-HT uptake experiments, 300 µL of GFP-hSERT expressing cells were added to the 
glass chamber and the rotator lowered into the center and rotated at 2000 rpm until a stable 
baseline recording was achieved.  Single additions of 5-HT, from 0.25-5.0 µM were added to 
the cell suspension, and uptake recorded for 20 s.  A 10 µL aliquot of cell suspension 
containing 0.4% tryphan blue was used to determine cell number using a haemacytometer.  
For the MDMA time points and activator/inhibitor experiments, a 5-HT concentration of 1.5 
µM was used.  For the kinetic experiments, a range of 5-HT concentrations was used, ranging 
from 0.25-5 µM.  Transfection percentages were calculated by visualization of GFP-hSERT 
positive cells using a fluorescent microscope (AX70, Olympus, Mt Waverly, Australia). 
2.6.3 Data Analysis 
5-HT uptake by SERT was determined from a 10 s period directly after addition of 5-HT.  
Microsoft Office Excel was used to plot the data and generate a linear regression.  A linear 
regression with an R
2
 value less than 0.95 was discarded from this study.  The change in 
current recorded from measurement period of 5-HT uptake by the cells was transformed into 
µmol/s using the standard concentration curve generated at the beginning of the experiment.  
Using data generated from the standard curve and cell numbers SERT uptake was expressed 
in pmol/s/10
6
 cells.  The values were then entered into GraphPad Prism to calculate the 
kinetic data.  For HEK-293 cells a nonlinear regression (one-site binding hyperbole) was 
fitted to the data and Vmax and Km values could be calculated.  Student t-tests and one-way 
ANOVA were used to determine the statistical significance.   
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3 Chapter 3: Validation of SERT antibody specificity 
3.1 Introduction 
In recent years there has been increasing interest in the molecular characteristics and 
regulatory process of SERT.  This has lead to the production of numerous SERT-specific 
antibodies.  A review of the literature shows that there is much discrepancy and uncertainty 
over the identification of the molecular size of SERT, with a diverse pattern of SERT 
expression being reported (Table 3:1).  The discrepancy in the literature has lead to 
speculation over the neurotoxicity of MDMA, as well as controversy over other SERT-
related findings.  Whether or not MDMA has the potential to decrease SERT protein after 
MDMA treatment is debated throughout the literature, largely due to the fact that there is no 
consensus over which band represents SERT (Wang et al. 2005; Xie et al. 2006; Kivell et al. 
2010).  Reports from our lab show that there is no change in SERT abundance after MDMA 
treatment, instead we report that there is a redistribution of SERT from the plasma membrane 
to the intracellular compartment in cells transiently expressing SERT (Kivell et al. 2010).  In 
contrast, reports from Wang et al. (2005) state that they did not observe any change in SERT 
distribution in brain tissue following MDMA administration. However images from their 
Western blot experiments show that the protein loaded in the gels were heavily overloaded 
and so may affect the analysis of their results.  SERT heterologously expressed in cell lines is 
found at different molecular weights than SERT constitutively expressed in brain tissue or 
platelets.  Some studies report a dominant non-glycosylated 60 kDa form of SERT which is 
expressed endogenously and trafficked to the outer membrane (Chamba et al. 2008).  Yet 
another study reports a diffuse 63-68 kDa immunoreactive band in rat brains (Xie et al. 
2006).  Endogenous SERT in the human brain and platelets have been also been identified as 
76 kDa and 94 kDa respectively (Qian et al. 1995).  Post-translational modifications have 
been attributed for the difference in mobility of the SERT protein.  Mutational studies (Tate 
and Blakely 1994) and experiments (Melikian et al. 1996; Cai et al. 2005) on DAT and NET 
have shown increasing evidence for the importance of N-glycosylation for correct folding of 
the transporters, therefore possibly playing a role in regulation and surface expression.  A 
study on the rat brain identified a 70 kDa glycosylated form of SERT which when de-
glycosylated creates a 50 kDa species (Wang et al. 2005).  SERT generated in cell lines such 
HEK-293 cells render a broad 85-95 kDa band which is N-glycosylated (Chamba et al. 2008). 
Despite a large number of studies, SERT-specific antibodies have not been able to 
characterize SERT at the protein level due to the lack of consensus regarding its size or 
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isoform and general lack of specificity.  For these reasons our laboratory utilizes a cell system 
where the GFP-tagged SERT can be directly visualized.  This overcomes the limitations of 
the available antibodies (Kivell et al. 2010).  
This chapter investigates the discrepancy between SERT antibodies by comparing two 
SERT-specific antibodies that are commercially available.  Both are from polyclonal 
backgrounds, with one being directed to the N-terminal (Sigma Aldrich, USA), and the other 
to the C-terminal (Santa Cruz supplied by Thermofisher, Auckland, NZ) of the human SERT 
protein.  Since our cellular system employs a GFP tag, we are able to directly visualize SERT 
using a laser scanner to read the fluorescent gels.  This allows for a comparison between what 
bands the SERT-specific antibodies identify, and what bands are identified through the direct 
detection of SERT via fluorescent GFP.  Detailed methods can be found in Section 2.3. 
 
Table 3:1: Literature review of the molecular characteristics of SERT.   
Table adapted from Chamba et al. (2008) 
Species Cell type Source Size (kDa) Reference 
Human HEK-293 cDNA 96, 76 (Ramamoorthy et al. 1998) 
Human HEK-293 cDNA 85-95, 60 (Frankhauser et al. 2006) 
Human N2A cDNA 100, 85 (Kivell et al. 2010) 
Human HEK-293 cDNA 85-95, 70, 60 (Chamba et al. 2008) 
Rat  Brain Endogenous 50 (Kivell et al. 2010) 
Rat HeLa cDNA 61 (Qian et al. 1995) 
Rat Brain Endogenous 70, 50 (Wang et al. 2005) 
Rat Brain Endogenous 70 (Rothman et al. 2003) 
Rat Brain Endogenous 63-68 (Xie et al. 2006) 
Rat  Platelet Endogenous 100 (Jayanthi et al. 2005) 
Human HEK-293, 
N2A 
cDNA 103, 75 This study 
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3.2 Aim 
This experiment aimed to investigate if there are discrepancies in SERT protein 
immunolabeling.  To do this we immunolabeled Western blots using two different SERT-
specific antibodies in both HEK-293 and N2A cells transfected with GFP-hSERT.  
Immunolabeling from the antibodies was compared to direct detection of SERT via its GFP 
tag. 
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3.3 Results 
Figure 3:1 shows non-transfected HEK-293 cells (lanes 1 and 2) and transiently transfected 
GFP-hSERT HEK-293 cells (lanes 3, 4 and 5) probed with Antibody 1 at a dilution of 1:500 
(a) and 1:1000 (b).  Non-transfected HEK-293 cells were run as controls to test the antibodies 
for non-specific binding.  From this Western blot it appears that there is residual 
immunolabeling in the non-transfected cells, whether this is evidence of non-specific binding 
is not clear (Figure 3:1).  There is no difference in the pattern of staining using the two 
different antibody concentrations as seen in Figure 3:2.  However loading protein 
concentrations above 50 µg causes the blot to become saturated and the bands appear 
significantly more diffuse and undefined (Figure 3:1 and Figure 3:2). 
Figure 3:2 shows that there is no significant difference in the pattern of staining between 
Antibody 1 and Antibody 2 (lanes 3, 4 and 5).  Both antibodies identify a dominant band at 
103 kDa and 75 kDa, with the same pattern of non-specific binding.  The molecular weight of 
SERT that Antibody 1 is predicted to identify is 70 kDa according to the manufacturer’s 
protocol.  Antibody 2 is predicted to identify SERT at 83 kDa according to the 
manufacturer’s protocol.   
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Figure 3:1: Western blot of HEK-293 cells transfected with GFP-hSERT and probed 
with Antibody 1. A dilution of 1:500 (a) and 1:1000 (b) was used to probe the membranes.  
Pictured with the immunoblot (right) is the fluorescent gel (left) corresponding to the blot.  
Lanes are indicated with numbers (1-5) with the amount of protein loaded denoted 
underneath.  Both non-transfected and GFP-hSERT transfected HEK-293 cells were loaded. 
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Figure 3:2: Western blot of HEK-293 cells transfected with GFP-hSERT and probed 
with Antibody 2.   
A dilution of 1:1000 was used to probe the membranes.  Pictured is the fluorescent gel 
corresponding to the immunoblot. Lanes are indicated with numbers (1-10) with the amount 
of protein loaded denoted underneath.  Both non-transfected and GFP-hSERT transfected 
HEK-293 cells were loaded.  
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Figure 3:3 shows a Western blot of N2A cells either transfected with GFP-hSERT or non-
transfected wild-type.  Antibody 2 was used to probe the cell lysates at a dilution of 1:1000.  
With the difficulty encountered by poor transfection rates and inefficient transfer rates of the 
protein from the gel to the membrane, only this antibody was able to be investigated at this 
dilution.  This antibody picked up a dominant immunoreactive band at 103 kDa and 75 kDa 
with the rest of the blot having a similar staining pattern to that of HEK-293 cells (Figure 3:1 
and Figure 3:2). 
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Figure 3:3: Western blot of N2A cells transfected with GFP-hSERT and probed with 
Antibody 2 at a dilution of 1:1000.  
Lanes are indicated with numbers (1-10) with the amount of protein loaded denoted 
underneath.  Both non-transfected and GFP-hSERT transfected N2A cells were loaded.  
Pictured is the fluorescent gel corresponding to the immunoblot. 
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3.4 Discussion 
Initial experiments were performed to investigate if any difference in the pattern of GFP-
hSERT expression could be seen when immunolabeled with two different anti-SERT 
antibodies.  We chose widely used commercially available antibodies directed at both the C 
terminal (antibody 1) and the N terminal (antibody 2).  It was advantageous to be able to 
validate the cellular model utilized throughout this project by comparison of the pattern of 
SERT expression using antibodies versus the detection of the GFP-tag attached to hSERT. 
What is most intriguing about this experiment was that non-transfected HEK-293 and N2A 
cells showed a similar staining pattern to GFP-hSERT transfected cells. A study carried out 
by Chamba et al. (2008) reported that HEK-293 cells contain endogenous SERT.  This 
finding was supported by a study which carried out a Clonetech gene array platform 
confirming that SERT mRNA is abundantly expressed in wild-type HEK-293 cells (Shaw et 
al. 2002).  Bands appear at 45, 60 and 70 kDa in wild-type and SERT transfected HEK-293 
cells and have been labeled the major SERT protein species.  The diffuse 85-95 kDa band is 
most dominant in the SERT transfectants (Chamba et al. 2008).  This is in partial agreement 
with our study where our two dominant diffuse bands are seen at 103 kDa and 75 kDa in 
GFP-hSERT transfected HEK-293 cells.  Whether the staining pattern observed in the non-
transfected lanes is residual non-specific antibody binding, or whether there is SERT present 
in these cells is unclear.  
Due to the difficulty in transfection efficiency being poor of N2A cells with GFP-hSERT, it 
was not possible to probe with both antibodies.  Some difficulty was encountered with 
transfer of protein from the gel to the PVDF membrane, and after optimization of the transfer 
buffer, only the membrane from Figure 3:3 was successfully able to be blotted with Antibody 
2.  Since our lab and further experiments from this study concentrates on a cell system where 
hSERT is tagged with GFP, it would have been interesting to show what an antibody directed 
to GFP identified compared to what the fluorescent gels of GFP-hSERT showed.  It would 
have been a good method validation to show that a GFP-specific antibody identifies the same 
pattern of SERT expression that is seen after reading the gels on the laser scanner.  A 
comparison of this to the SERT-specific antibodies would be the next step in validating the 
specificity debate over the identification of SERT.  Unfortunately due to time constraints and 
trouble-shooting, the GFP-specific antibody was not able to yield a successful Western blot. 
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In an attempt to identify the dominant bands appearing in the above Western blots, a review 
of the literature reporting different SERT molecular sizes was carried out (Table 3:1).  It is 
clear that there are various patterns of SERT expression depending on whether it is expressed 
in cell lines or endogenously in brain tissue or platelets.  However there is no consensus over 
the SERT protein size or isoform regardless of the background or species it is expressed in 
(Table 3:1) (Chamba et al. 2008).  Indeed, in this project we find two bands from the 
transfected cell lines with molecular weights of 103 kDa and 75 kDa which we identify as 
SERT, however it is worth mentioning that the manufacturers state the expected molecular 
size for SERT is 70 kDa (antibody 1) and 83 kDa (antibody 2).  Discrepancy could arrive 
from differences in experimental protocols; the amount of protein loaded in gels can alter 
protein migration, and storage and batches of antibodies tend to vary between studies and can 
affect reported results.  Post-translational modification can be attributed for differences in 
SERT mobility, and with the knowledge that the SERT protein exists in N-glycosylated and 
un-glycosylated forms, this helps in identifying the different forms of SERT in a gel.  
Chamba et al. (2008) report that the broad 85-95 kDa band appearing in their blots is a 
heavily N-glycosylated form of SERT in transfected HEK-293 cells.  Removal of the N-
glycans achieve bands that appear at 60 and 70 kDa which correspond to those found 
expressed constitutively in non-transfected cells, leading this group to conclude that non-
glycosylated SERT exists in HEK-293 cells.  Keeping the results from the literature in mind 
and combining them with our previous knowledge of SERT characteristics, this study 
concluded that in the above Western blots, the diffuse band found at 103 kDa in HEK-293 
cells and N2A cells transfected with hSERT is the N-glycosylated form of SERT. The smaller 
band found at 75 kDa in HEK-293 cells and in N2A cells we suggest could be the non-
glycosylated form.  We are hesitant to suggest what the band identified at 75 kDa in the non-
transfected cell lanes could be; whether it non-specific binding or a form of SERT is not 
clear.  Further research into SERT antibody specificity is required before more conclusions is 
made.  
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4 Chapter 4: Investigating the effects of MDMA on SERT function in a 
cell model 
 
4.1 Introduction 
It is commonly known that SERT function is regulated by trafficking between the plasma 
membrane and intracellular compartment through a series of post-translational modifications 
(Ramamoorthy et al. 1998; Howell and Kimmel 2008; Kivell et al. 2010). Studies carried out 
in our laboratory have shown that MDMA is able to rapidly internalize SERT from the 
plasma membrane into the cytosol in HEK-293 and N2A cells (Kivell et al. 2010).  What is 
not clear, however, is the mechanism by which this internalization occurs.  PKC is an 
intracellular protein known to be involved in regulating SERT expression and function 
(Jayanthi and Ramamoorthy 2005).  The question this chapter sought to investigate was 
whether changes in SERT function caused by MDMA were via PKC-dependent signaling 
pathways. 
Cell models have been utilized throughout this study as they allow for greater manipulation 
when studying the effects of drugs on monoamine transporters than is possible in a whole 
animal or tissue samples. HEK-293 cells are a well-established cell model used to investigate 
monoamine transporter regulation and have been shown to contain many of the relevant cell 
signaling pathways.  HEK-293 cells are derived from cells transfected with adenovirus 5, and 
despite being from a kidney origin have been shown to possess proteins from a neuronal 
background (Shaw et al. 2002).  N2A cells are also from a neuronal origin and therefore 
contain many of the relevant signaling pathways (Klebe and Ruddle 1969). 
Traditional methods for studying SERT function in the brain include radioactive 5-HT uptake 
(Ramamoorthy et al. 1998), high-speed chronoamperometry (HSC) (Perez and Andrews 
2005) and fast scan cyclic voltammetry (FSCV) (John and Jones 2007; Hashemi et al. 2009).  
These techniques have been used to measure SERT function in cells, synaptosomes and in 
vivo tissue systems.  Another technique used to measure neurotransmitter transporter function 
is called rotating disc electrode voltammetry (RDEV) (Earles and Schenk 1998).  This 
electrochemical technique is widely used in studies investigating the release and uptake of 
norepinephrine and dopamine by the neuronal monoamine transporters in both cell and brain 
tissue models (Burnette et al. 1996; Earles and Schenk 1998; Chen et al. 1999).  Recently, 
RDEV has been validated for the measurement of SERT function in synaptosomes (Hagan et 
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al. 2010; Hagan et al. 2011).  The rotation of the glassy carbon electrode at 2000 rpm allows 
for the solution in the chamber to remain well-mixed throughout the experimental time and 
the voltage applied is specific to oxidize the monoamines present in the chamber.  The 
rotation of the electrode draws neurotransmitters towards the submerged electrode surface 
where they oxidize, releasing 1 or 2 electrons which produce the resulting current (Earles and 
Schenk 1998; Hagan et al. 2010).  The magnitude of the current is directly related to the 
concentration of free monoamine substrate in the sample.  Therefore, as monoamines are 
transported into the cells or tissue preparations in the chamber, the current will decrease 
accordingly due to the decrease in free monoamine able to be oxidized (Earles and Schenk 
1998). The magnitude of the current measured at the solid electrode surface can be defined by 
the Levich equation: 
IL = 0.62nFACD
2/3
v
-1/6ω1/2 
Where IL is the limiting current, n is the number of electrons transferred per mole, F is the 
Faradays constant, A is the area of the electrode in cm
2
, D is the diffusion coefficient of the 
electroactive substrate in cm
2
/s, C is the concentration of the electroactive substrate in the 
sample solution in mM, v is the kinematic viscosity of the solution in cm
2
/sec, ω is the 
singular velocity of rotation in rad/sec, where ω = 2πN, and N is the number of rotations per 
second (Earles and Schenk 1998). 
At the time of this study, there was no published data using RDEV to measure SERT function 
in cultured cells.  Therefore, much of the protocol carried out for this project is based upon a 
recently published PhD thesis completed in our lab (Simonson 2011).  Simonson (2011) 
sought to characterize SERT function in HEK-293 cells expressing GFP-hSERT, and the 
same experimental set-up was used in this study for the two cell lines being investigated, N2A 
and HEK-293 cells. RDEV was used to investigate changes in SERT function after MDMA 
treatment by measuring 5-HT uptake.  PKC activation by β-PMA causes a down-regulation 
in SERT function (Jayanthi et al. 2005).  To establish whether MDMA works through a PKC-
driven signaling system to alter SERT function, cells expressing SERT were pre-treated with 
a PKC inhibitor, Bis I.  Bis I is a potent and selective PKC inhibitor, and studies have shown 
that it blocks the activation of PKC by β-PMA in astrocytes (Yasuda et al. 2011).  Previous 
studies in tissue and cell preparations have shown that pre-treatment with Bis I for 30-90 min 
(Nair and Gudelsky 2004; Ramamoorthy et al. 2007) is sufficient to inhibit PKC.  In this 
chapter RDEV was used to measure any changes in 5-HT uptake in cells treated with MDMA 
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in the presence or absence of Bis I.  The ability of Bis I to block MDMA-induced effects on 
SERT function could signify that MDMA is targeting the PKC pathway to regulate SERT. 
4.2 Aim 
Using RDEV to measure SERT function in HEK-293 and N2A cells transfected with GFP-
hSERT, we aim to determine if MDMA modulates SERT via a PKC-dependent pathway  
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4.3 Results 
4.3.1 Effect of MDMA on SERT function 
MDMA is known to compete with 5-HT for uptake by SERT (Howell and Kimmel 2008).  
To ensure that changes in 5-HT uptake seen after MDMA treatment was not due to residual 
MDMA in the cell suspension competing for uptake, a wash-out control was performed 
(Figure 4:1).  MDMA (10 µg/mL) was added to a 35 mm dish containing GFP-hSERT 
transfected cells for 30 s and then removed.  5-HT uptake was then measured using RDEV 
with a single addition of 5-HT at 1.5 µM.  No change in 5-HT uptake was observed compared 
to control (Figure 4:1).  This shows that MDMA is able to be washed away and is no longer 
present to compete for uptake at SERT.  The short time course used for this experiment (10 s) 
was not sufficient to measure changes in SERT trafficking which typically occurs after at 
least 5 min. 
To determine whether MDMA causes a down-regulation of SERT function we measured 
SERT function using RDEV in HEK-293 and N2A cells transiently transfected with GFP-
hSERT.  Cells were incubated with 10 µg/mL of MDMA for 5, 10, 30, 60 and 90 min.   
HEK-293 cells incubated with MDMA for 5 min show that 5-HT uptake is significantly 
decreased compared to controls (Figure 4:2A), with MDMA reducing uptake by 47% 
(p<0.01).  After a 10 min incubation with MDMA, uptake was reduced by 63% (p<0.001).  
This decrease in 5-HT uptake persisted until the 90 min time point (p<0.01).  This 
demonstrates that MDMA is able to cause a functional down-regulation due to the significant 
decrease seen in 5-HT uptake compared to vehicle-treated cells. 
The same experiment was repeated in N2A cells transiently transfected with GFP-hSERT.   
Interestingly, a decrease in 5-HT uptake was only seen with cells incubated with MDMA for 
5 and 10 min (Figure 4:2B).  At 5 min and 10 min, 5-HT uptake was significantly decreased, 
with 43% decreased uptake (p<0.01 and p<0.05 respectively), suggesting a reversible, more 
transient decrease in SERT function.   
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Figure 4:1: MDMA wash-out control.  
 HEK-293 (A) and N2A (B) cells transfected with GFP-hSERT were incubated with MDMA 
(10 µg/mL) for 30 s and then washed with 1 x PBS before a single 5-HT (1.5 µM) addition.  
There was no significant difference in 5-HT uptake between control-treated (PBS) 
preparations and MDMA wash-out treatments, (n = 4 preparations).  Student t-test used for 
statistical analysis. 
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Figure 4:2: Effect of MDMA on 5-HT uptake in HEK-293 and N2A cells transfected 
with GFP-hSERT.   
HEK-293 cells (A) and N2A cells (B) were incubated with MDMA (10 µg/mL) for 5-90 min 
before 5-HT (1.5 µM) addition.  MDMA caused a decrease in 5-HT uptake within 5 min for 
both cell lines when measured using RDEV.  However, only HEK-293 cells showed a 
significant decrease in 5-HT uptake for the time period of 90 min. (n = 3-4 preparations).  
Data points represent mean ±SEM.  One-way ANOVA followed by Bonferroni post test, 
*p<0.05, **p<0.01, ***p<0.001. 
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4.3.2 Effect of PKC activator β-PMA on SERT function 
Once we established that MDMA caused a functional down-regulation of SERT through 
RDEV methods (Figure 4:2), the next step was to investigate whether it was caused by 
activation of PKC.  Inhibition of SERT function occurs upon PKC activation, causing a 
reduction in 5-HT uptake (indicated by a decrease in Vmax) with little or no change in the 
affinity of SERT for 5-HT (no change in Km) (Qian et al. 1997).  Addition of 1 µM β-PMA 
has been previously shown to decrease SERT function in HEK-293 cells within 20-60 min 
(Qian et al. 1997; Kivell et al. 2010).  In this study, HEK-293 and N2A cells transiently 
transfected with GFP-hSERT were pretreated with 1 µM β-PMA for 30 or 60 min, followed 
by analysis of 5-HT uptake by RDEV.  In HEK-293 cells, the 30 min pre-treatment with β-
PMA significantly decreased uptake by 35% compared to controls (p<0.05) (Figure 4:3A).  
Treatment for 60 min reduced uptake by 45% (p<0.01) (Figure 4:3A).  Interestingly, N2A 
cells did not show a significant decrease in 5-HT uptake after incubation with β-PMA for 
either 30 min or 60 min (Figure 4:3B).  However it should be noted that there is a trend 
towards a decrease in 5-HT uptake after a 30 min incubation with β-PMA (p=0.07, Student t-
test). 
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Figure 4:3: The effect of the PKC activator β-PMA on 5-HT uptake in HEK-293 and 
N2A cells transfected with GFP-hSERT.   
HEK-293 (A) and N2A (B) cells were incubated with 1 µM of β-PMA for 30 or 60 min 
before 5-HT addition (1.5 µM).  A significant decrease in 5-HT uptake was seen in HEK-293 
cells after 30 and 60 min β-PMA incubation (n = 4 preparations).  In N2A cells there is a 
trend towards a decrease in 5-HT uptake after a 30 min incubation with β-PMA (p=0.07, 
Student t-test) (n = 5-7 preparations). *p<0.05, **p<0.01. 
 
p = 0.07 
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4.3.3 Effect of MDMA on 5-HT uptake after PKC inhibition 
Results presented in Figure 4:2A and Figure 4:3A show that both MDMA treatment and PKC 
activation significantly decreased 5-HT uptake by SERT in HEK-293 cells.  In N2A cells, 
MDMA causes a significant decrease in 5-HT uptake, with β-PMA treatment showing a trend 
towards a decrease in 5-HT uptake (Figure 4:2B and Figure 4:3B).  To establish whether 
MDMA is causing this down-regulation through PKC, Bis I pre-treatment was used to inhibit 
PKC.  In this study, HEK-293 and N2A cells transiently transfected with GFP-hSERT were 
pretreated with 200 nM of Bis I for 30 min. MDMA (10 µg/mL) was then added for 5 min 
and 5-HT uptake measured.  Pre-treatment with Bis I show that in both HEK-293 cells 
(Figure 4:4A) and N2A cells (Figure 4:4B), 5-HT uptake was not reduced after MDMA 
treatment.    However cells in the absence of Bis I show a significant decrease in 5-HT uptake 
after MDMA treatment (Figure 4:4).  This suggests that PKC inhibition prevents the effects 
MDMA has on SERT function.   
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Figure 4:4: Effect of MDMA on 5-HT uptake after PKC inhibition by Bis I in HEK-293 
and N2A cells transfected with GFP-hSERT.   
HEK-293 (A) and N2A (B) cells transfected with GFP-hSERT were incubated with either 200 
nM of Bis I for 30 min, or incubated with 200 nM of Bis I for 30 min followed by incubation 
with 10 µg/mL of MDMA for 5 min before 5-HT addition (1.5 µM).  5-HT uptake levels 
were compared to vehicle-treated controls (vehicle 1 is DMSO, vehicle 2 is PBS).  
Transfected cells were also incubated with 10 µg/mL of MDMA for 5 min before 5-HT 
addition (1.5 µM).  Both cell lines show that pre-treatment with Bis I prevents the decrease in 
5-HT uptake that MDMA causes, with 5-HT uptake levels comparable to vehicle treated 
control levels. (n = 4-7 for N2A cell preparations, n = 3-5 for HEK-293 cell preparations).  
Data points represent the mean ± SEM.  One-way ANOVA followed by Bonferroni post test, 
**p<0.01. 
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4.4 Discussion 
At the beginning of this project there were no published reports using RDEV methods to 
measure SERT function in transfected cell lines. The experimental parameters used in this 
study are based upon unpublished data from our laboratory which established RDEV 
techniques to measure SERT function in both HEK-293 cells transfected with hSERT, and rat 
brain tissue samples.  Since this time, two very recent publications by Hagan et al. (2010) and 
Hagan et al. (2011) have provided the first use of RDEV to measure SERT.   This study used 
whole mouse brain synaptosomes.  The protocol established by Hagan et al. is very similar to 
that used in the current study.  The main difference is that we measured 5-HT oxidation at 
+450 mV in isolated cell cultures, where Hagan et al. measured the current produced at +550 
mV.  The values from the study by Hagan et al. and this study are both within the measurable 
range, but because we used a lower voltage, our 5-HT signal was 2.5 times lower (0.084 ± 
0.004 nA/nM compared to 0.21 ± 0.01 nA/nM). 
The principal aim of this experiment was to identify the cellular signaling pathway 
responsible for the decrease in SERT function following exposure to MDMA.  Previous 
studies have shown that MDMA causes a release of 5-HT into the extracellular space and 
promotes an increase in activity of PKC (Kramer et al. 1997; Kramer et al. 1998).  To 
investigate the time of maximal effect on SERT function, MDMA was incubated for 90 min 
with the two cell lines transiently transfected with GFP-hSERT, with initial 5-HT uptake 
measured at 5, 10, 30, 60 and 90 min.  It was expected that MDMA would cause a rapid and 
sustained decrease in 5-HT uptake as previous cell surface biotinylation and a microscopy 
technique called Total Internal Reflection Fluorescence microscopy (TIRFM) studies have 
shown that SERT is internalized after MDMA treatment (Kivell et al. 2010).  Indeed, HEK-
293 cells transfected with GFP-hSERT displayed a significant decrease in 5-HT uptake (47-
63%) following MDMA treatment in a rapid (within 5 min) and sustained (up to 90 min) 
manner.  However N2A cells transiently transfected with GFP-hSERT, MDMA treatment 
caused a significant decrease in 5-HT uptake compared to vehicle treated cells (43%) at 5 and 
10 minute (Figure 4:2B).  5-HT uptake was returned to levels comparable to vehicle treated 
cells with longer incubation times (30, 60 and 90 min).  It is unclear why N2A cells only 
show a change in SERT function after a short incubation with MDMA whereas HEK-293 
cells show a sustained decrease in SERT function after MDMA treatment.  This suggests that 
SERT may be differentially regulated in N2A cells compared to HEK-293 cells with the 
activation of certain signaling cascades having variable sensitivity for MDMA.  The level of 
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5-HT uptake in N2A cells compared to HEK-293 cells is also markedly different.  The 
amount of 5-HT uptake in N2A cells is apparently half of that that is seen in HEK-293 cells.  
N2A cells do not transfect with GFP-hSERT to the same expression levels.  These differences 
of 5-HT uptake in the cell lines may be due to the expression of less functional SERT on the 
cell surface. 
Previous studies carried out by our lab have attempted to identify the pathway responsible for 
MDMA-induced regulation of SERT (Kivell et al. 2010).  In particular p38 MAPK was 
investigated as to its role in MDMA-induced SERT down-regulation.  Several studies have 
identified p38 MAPK as a known regulator of SERT membrane expression (Samuvel et al. 
2005; Zhu et al. 2005; Oz et al. 2010).  However it was found that p38 MAPK was not 
activated in response to MDMA treatment in GFP-hSERT transfected HEK-293 cells (Kivell 
et al. 2010).  
There are several studies that show PKC is a regulator of SERT function and that activation 
of PKC by -PMA leads to a decrease in SERT activity (Jayanthi and Ramamoorthy 2005; 
Jayanthi et al. 2005).  Here we show that treatment with β-PMA for 30 or 60 min causes a 
decrease in 5-HT uptake in HEK-293 cells transfected with GFP-hSERT.  What is interesting 
is that the same treatment with β-PMA did not cause a significant decrease in 5-HT uptake in 
N2A cells expressing GFP-hSERT (p<0.07 at 30 min).  It is unclear why N2A cells respond 
differently to β-PMA and MDMA treatment, it suggests that these cells are regulated in a 
different manner compared to HEK-293 cells.  Pre-treatment with the PKC inhibitor, Bis I 
was able to block the decrease in 5-HT uptake caused by MDMA in both cell lines.  These 
preliminary results suggest that MDMA may be regulating SERT function through a PKC 
signaling system in transfected cell cultures. 
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5 Chapter 5: Investigating the effect MDMA has on the surface 
expression of SERT in a cell model 
5.1 Introduction 
In Chapter 4 we present evidence to suggest that MDMA causes a functional down-regulation 
of SERT in both N2A and HEK-293 cells using RDEV methods. With pre-treatment of a 
PKC inhibitor, however, this functional down-regulation was blocked. To the best of our 
knowledge PKC is part of the first signaling pathway to be identified in playing a role in 
MDMA-mediated SERT regulation.  Previous studies have shown that MDMA treatment and 
PKC activation results in a down-regulation of SERT function.  This has been shown to be by 
a decrease in SERT surface expression through internalization (Jayanthi et al. 2005; Kivell et 
al. 2010).  Kinetic data obtained using RDEV techniques gives detailed information about 
Michaelis-Menton kinetics.  RDEV is able to show whether a change in 5-HT uptake is due 
to a change in affinity of a substrate for a transporter (Km) or due to a change in cell surface 
expression or modulation of the transporter by post-translational modifications (Vmax) (Earles 
and Schenk 1998; Chen et al. 1999).   
Radioactive uptake studies are commonly used to provide information on transporter kinetics 
and densities, however limitations of using such a technique include the inability to measure 
monoamine uptake in real time or provide data on initial uptake kinetics.  High-speed 
chronoamperometry (HSC) and fast scan cyclic voltammetry (FSCV) are able to provide 
kinetically resolved, real-time information for both in vivo and in vitro neurotransmitter 
events; however, they are technically challenging and require expensive, specialized 
equipment. RDEV is able to provide real-time, high temporal resolution measurements (can 
take up to 1000 measurements per second) in both cell suspensions and tissue homogenates 
expressing monoamine transporters.  A very recent study published during the course of this 
study characterized RDEV technique for the measurement of SERT function.  Mouse whole 
brain synaptosomes were used to show the difference in SERT kinetics between wild-type 
and SERT-knock-out mice.  Wild-type mice displayed a higher uptake rate than the 
homozygous or heterozygous knockouts, with uptake being inhibited by the selective 
serotonin reuptake inhibitor (SSRI) paroxetine hydrochloride (Hagan et al. 2010).  This study 
elegantly showed that in tissue samples, RDEV can be used to sensitively measure the 
difference in 5-HT uptake rate between the three mouse genotypes.  Radioactive uptake 
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methods could not distinguish differences in SERT function between heterozygous SERT 
knockout mice and wild-type mice (Bengel et al. 1998).   
In this study we use cell surface biotinylation and Total Internal Reflection Fluorescence 
microscopy techniques (TIRFM) in conjunction with functional kinetic data to establish 
whether the MDMA-induced down-regulation of SERT seen in Chapter 4 was due to changes 
in cell surface expression. 
Cell surface biotinylation is an established biochemical technique routinely used to measure 
the change in cell surface expression of monoamine transporters (Bolan et al. 2007; Zapata et 
al. 2007).  Recently, published data from our lab used cell surface biotinylation techniques to 
show that MDMA (10 µg/mL) induces a rapid (within 5 min) and sustained (up to 90 min) 
decrease of GFP-hSERT from the cell surface fraction (24%) with a corresponding increase 
in the intracellular fraction (30%).  Activation of PKC by 1 µM of β-PMA for 30 min was 
sufficient to cause a 23% decrease in the cell surface fraction with a corresponding increase 
of 30% in the intracellular fraction.  This was shown in both N2A and HEK-293 cells (Kivell 
et al. 2010). Using biotinylated whole cell extracts of transfected HeLa cells it has been 
shown that β-PMA is able to alter SERT cell surface density (Prasad et al. 2005). HeLa cells 
transiently expressing hSERT with 10 µM of β-PMA for 15 min was sufficient to cause a 
40% down-regulation of 5-HT transport activity (Prasad et al. 2005).  This down-regulation 
was also blocked with the PKC inhibitor Bis I.  Cell surface biotinylation of SERT from rat 
platelets has also shown that a 30 min exposure to β-PMA causes a 80% reduction in surface 
SERT, with a corresponding increase in the intracellular fraction (Jayanthi et al. 2005).  This 
effect was blocked by 250 nM of the PKC inhibitor Bis I.  
Even though cell surface biotinylation studies have been successfully used to investigate cell 
surface changes, as outlined above, it must be recognized that there are limitations to this 
technique.  Cell surface biotinylation measures changes in a pool of heterologous cells, and 
so the sensitivity of this technique can be questioned if the cells are not all consistently 
expressing the same amount of SERT protein.  This can lead to variable results over different 
dishes and between different cell lines.  A study conducted by Furman et al. (2009) illustrated 
that as biotin has access to only the proteins found on the outer cell surface membrane and 
any protein located within cell membrane invaginations would be left unbound.  This could 
invariably lead to the internal fraction of the biotinylation being larger than what it really is, 
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as the proteins would be counted as intracellular rather than cell surface.  This is why this 
technique is often partnered with sensitive microscopy techniques, such as TIRFM. 
Previous studies with HEK-293 cells have successfully used TIRFM to show that GFP-
hSERT cell surface expression is decreased upon MDMA exposure (Kivell et al. 2010).  
Furman et al. (2009) have also shown that N2A cells stably expressing a yellow fluorescent 
tagged- dopamine transporter (DAT) respond to dopamine and amphetamine by increasing 
cell surface expression of YFP-hDAT.  These studies demonstrate how TIRFM can be used 
as a sensitive technique to measure and monitor cell surface expression of fluorescently-
tagged proteins in live cells.  TIRFM is a microscopy technique where the laser beam used to 
excite the fluorescent tag is bent greater than the critical angle of the sample.  This results in 
an evanescent field of 100 nm from the point of laser-focus which excites any fluorescent 
molecules within it.  This represents the proteins found at the cell surface. The critical angle 
is defined by: 
θc = sin
-1
(n1/n3) 
From this equation, the critical angle is given by θc, where the refractive index of the liquid is 
n1 and the refractive index of the solid is n3 (the solid is taken as the glass bottom of the dish) 
(Axelrod 2001).  When the TIRF angle is greater than the critical angle the laser beam is 
entirely internally reflected rather than refracted through the sample.  This generates images 
that have very low background fluorescence (compared to images acquired with just epi-
fluorescence) and much greater detail.  The unique features of TIRFM allow it to be a useful 
technique for measuring changes in cell surface expression of live cells that contain 
fluorescent membrane proteins.  Since the evanenscent field is only set to a 100 nm 
penetration depth, this allows visualization of any trafficking/movement of the fluorophores 
from the membrane to the cytosol, or vice versa.  
The aim of using this technique was to exploit the high temporal and spatial resolution of 
TIRFM in order to investigate the dynamics of SERT trafficking upon MDMA and β-PMA 
application.  This technique was used as a more sensitive measure to couple with the results 
gained from the cell surface biotinylation experiments. 
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5.2 Aim 
We hypothesize that the MDMA-induced down-regulation of SERT is PKC-dependent.  To 
test this we treated HEK-293 and N2A cells transfected with GFP-hSERT with a PKC 
inhibitor, Bis I, and measured changes in cell surface expression using RDEV kinetic data, 
cell surface biotinylation and TIRFM.  
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5.3 Results 
5.3.1 Determination of SERT kinetics in cells transfected with GFP-hSERT following 
MDMA treatment. 
Control experiments were carried out using non-transfected HEK-293 (Figure 5:1) and N2A 
cells (Figure 5:3).  These experiments help to determine the non-specific decay or uptake of 
5-HT in the system.  For HEK-293 cells, the baseline uptake was linear, with the slope of the 
line equaling 6.31 pmol/s/10
6 
cells (r
2
 = 0.9235).   Kinetic data obtained for HEK-293 cells 
expressing GFP-hSERT subsequently had the non-specific baseline uptake subtracted.  The 
specific uptake curve for these cells followed Michaelis-Menten kinetics (Figure 5:2) with an 
average Vmax of 108.3 ± 33.5 pmol/s/10
6
 cells and a Km of 3.3 ± 1.6 µM (Table 5:1). 
Kinetic data was obtained from HEK-293 cells transfected with GFP-hSERT following a 5 
min incubation with MDMA (10 µg/mL) (Figure 5:2) and gave an average Vmax of 87.6 ± 
43.1 pmol/s/10
6 
cells and a Km of 5.7 ± 3.7 µM (Table 5:1).  Surprisingly there was no 
significant difference between the Km and Vmax values between the controls vs. MDMA-
treated cells.  This suggests that change in 5-HT transport was not due to a cell surface down-
regulation of SERT. 
In non-transfected N2A cells, the baseline decay slope to determine the non-specific uptake of 
the system was unusual  in that it generated a sigmoidal curve rather than the linear uptake 
seen in HEK-293 cells (Figure 5:3).  Interestingly when kinetic data was gathered for GFP-
hSERT transfected N2A cells, 5-HT uptake did not follow the Michaelis-Menton curve as is 
expected for monoamine transporters (Figure 5:3). Again this data was better fitted to a 
sigmoidal curve rather than the traditional Michaelis-Menten hyperbole curve.  This 
sigmoidal curve was also found for transfected N2A cells treated with MDMA for 5 min 
(Figure 5:4).  This was an interesting finding, and due to lack of previous studies carried out 
in N2A cells using RDEV techniques, Vmax and Km values could not be obtained. 
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Figure 5:1: Uptake of 5-HT in non-transfected and GFP-hSERT transfected HEK-293 
cells.   
Single additions of 5-HT were used to treat non-transfected and GFP-hSERT transfected 
HEK-293 cells.  The initial uptake was then measured.  Uptake from non-transfected cells 
(non-specific uptake) was subtracted from transfected cells to give specific 5-HT uptake by 
GFP-hSERT.  Data points represent the mean ± SEM (n = 1, non-transfected, n = 3-5, 
transfected cell preparations). 
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Figure 5:2: The effect of MDMA on SERT function in HEK-293 cells transiently 
transfected with GFP-hSERT.   
MDMA (10 µg/mL) was added to cells 5 min before 5-HT uptake was measured by RDEV.  
Single additions of 5-HT were used to treat GFP-hSERT HEK-293 cells.  Data points are 
mean ± SEM (n = 3-5 preparations). 
 
Table 5:1: Kinetic data from RDEV for control and MDMA treated cells.   
Values are the mean ± SEM (n = 3-5 preparations).   No significant difference was found in 
the values between control vs. MDMA-treated cells as shown by Student t-test. 
 
 
 
 
Treatment Vmax (pmol/s/10
6
 cells) Km (µM) 
Control 108.3 ± 33.5 3.3  ±1.6 
MDMA 87.6 ± 43.1 5.7 ± 3.7 
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Figure 5:3: Uptake of 5-HT in non-transfected and GFP-hSERT transfected N2A cells.   
Single additions of 5-HT were used to treat non-transfected and GFP-hSERT transfected N2A 
cells.  The initial decay/uptake was then measured.  Uptake from non-transfected cells (non-
specific decay) was subtracted from transfected cells to give the specific initial uptake of 5-
HT by GFP-hSERT.  Data points represent the mean ± SEM (n = 1-2, non-transfected, n = 3-
6, transfected cell preparations). 
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Figure 5:4: The effect of MDMA on SERT function in N2A cells transiently transfected 
with GFP-hSERT.   
MDMA (10 µg/mL) was added to cells 5 min before uptake was measured by RDEV.  Single 
additions of 5-HT were used to treat GFP-hSERT N2A cells Data points are mean ± SEM (n 
= 2-6 preparations). 
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5.3.2 Cell surface biotinylation 
5.3.2.1 SERT Trafficking in Response to MDMA and PKC Activation 
HEK-293 and N2A cells transfected with GFP-hSERT were incubated with 10 µg/mL of 
MDMA to investigate changes in cell surface expression of SERT. The mean band intensity 
was measured for each fraction to give a value for GFP-hSERT.  The values for each 
treatment were then normalized back to the vehicle-treated control, with the results shown as 
a fold change compared to vehicle.   
HEK-293 cells transfected with GFP-hSERT were treated with 10 µg/mL of MDMA for 
either 10 or 60 min (Figure 5:5). As shown by RDEV in the previous chapter, there is a 
functional down-regulation of SERT at these time points.  It is surprising then, that cell 
surface biotinylations did not show a significant decrease in the cell surface fraction of GFP-
hSERT as predicted, indicating that SERT was not being internalized. 
Previous work from our lab showed that, in N2A cells, MDMA is able to cause a rapid (with 
5 min) and sustained (up to 90 min) decrease of GFP-hSERT (Kivell et al. 2010).  
Interestingly, functional data obtained from RDEV in the previous chapter shows that there is 
only a significant change in SERT function with a 5 or 10 min incubation with MDMA.  
Dishes were therefore incubated with 10 µg/mL of MDMA for 5, 10 or 60 min in order to see 
if there would be difference in surface expression of SERT at these time points.  Surprisingly, 
cell surface biotinylations did not show a significant change in GFP-hSERT at any of the 
time points (Figure 5:6).  
 
  
67 
 
Vehicle Control MDMA 10min MDMA 60min
0.00
0.25
0.50
0.75
1.00
1.25 Intracellular
Cell Surface
Treatment
F
o
ld
 C
h
a
n
g
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:5: No change seen in GFP-hSERT cell surface fraction following MDMA 
treatment in HEK-293 cells.   
HEK-293 cells were treated with 10 µg/µL of MDMA for 10 min or 60 min.  There was no 
detectable change in cell surface expression after either MDMA treatment.   The vehicle 
control used was PBS.  Shown is a representative gel and Western blot for GFP-hSERT and 
GAPDH respectively. T = total fraction, I = intracellular fraction, C = cell surface fraction (n 
= 4-24).  Data is presented as average ± SEM.  One-way ANOVA followed by Bonferroni 
post test showed no significant differences from the control. 
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Figure 5:6: No change seen in GFP-hSERT cell surface fraction after MDMA treatment 
in N2A cells.   
N2A cells were treated with 10 µg/mL of MDMA for 5, 10 or 60 min.  There was no 
detectable change in cell surface expression with any of the treatments.  The vehicle control 
used was PBS.   Shown is a representative gel for GFP-hSERT with an accompanying 
Western blot for GAPDH below. T = total fraction, I = intracellular fraction, C = cell surface 
fraction (n = 4-17).  Data is presented as average ± SEM.  One-way ANOVA followed by 
Bonferroni post test showed no significant differences from the control. 
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Cell surface biotinylation of transfected HEK-293 and N2A cells treated with the PKC 
activator β-PMA for 30 min did not show a significant decrease of GFP-hSERT from the cell 
surface fraction (Figure 5:7 and Figure 5:8 respectively).  Multiple batches of β-PMA were 
tested as concern arose over the integrity of the stock solution.  However no significant 
decrease was seen of GFP-hSERT from the cell surface for either HEK-293 or N2A cells after 
treatment with new β-PMA for 30 min (Figure 5:7 and Figure 5:8 respectively).  N2A cells 
transfected with GFP-hSERT were treated for 20 min with β-PMA in case the time point of 
maximal activity was being missed, and was occurring earlier.  Figure 5.8 shows that no 
significant change in GFP-hSERT cell surface expression was seen. 
Activation of PKC by β-PMA requires an increased level of intracellular calcium (Samuvel et 
al. 2005).  N2A cells expressing GFP-hSERT were treated with 5 µM of ionomycin and 1 µM 
of β-PMA for 30 min.  Ionomycin is a compound that increases the levels of intracellular 
calcium.  This treatment caused a significant (p<0.001) 35% decrease of GFP-hSERT from 
the cell surface fraction compared to control (Figure 5.8). 
Due to time constraints, ionomycin and β-PMA treatment was not carried out on HEK-293 
cells. 
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Figure 5:7: No change seen in GFP-hSERT cell surface fraction after β-PMA treatment 
in HEK-293 cells.   
HEK-293 cells were treated with 1 µM of either original or new β-PMA solution for 30 min.  
There was no detectable change in cell surface expression after either β-PMA treatment 
compared to vehicle (PBS) treated controls.  Shown is a representative gel for GFP-hSERT 
and Western blot of GAPDH below. T = total fraction, I = intracellular fraction, C = cell 
surface fraction (n = 4-24).  Data is presented as average ± SEM.  One-way ANOVA 
followed by Bonferroni post test showed no significant differences from the control. 
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Figure 5:8: No change in GFP-hSERT cell surface fraction after β-PMA treatment in 
N2A cells but significant decrease after treatment with Ionomycin and β-PMA.  
 A significant decrease in GFP-hSERT surface expression was seen upon treatment with 
Ionomycin and β-PMA.  N2A cells were treated with 1 µM of either two batches (original and 
new) β-PMA solution for 20 min or 30 min.  There was no detectable change in cell surface 
expression with any β-PMA treatment.  N2A cells were also treated simultaneously with 5 
µM of Ionomycin and 1 µM of β-PMA for 30 min.  There was a significant 35% decrease of 
GFP-hSERT from the cell surface fraction using a One-way ANOVA followed by Bonferroni 
post test.  The vehicle control used was PBS.  Shown is a representative gel for GFP-hSERT 
and Western blot of GAPDH below. T = total fraction, I = intracellular fraction, C = cell 
surface fraction (n = 4-17).  Data is presented as average ± SEM. ***p<0.001. 
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5.3.2.2 SERT Trafficking in Response to Simultaneous PKC Inhibition and MDMA 
To determine if MDMA works through a PKC-dependent pathway, both HEK-293 and N2A 
cells expressing GFP-hSERT were treated for 30 min with the PKC inhibitor, Bis I (200 nM), 
prior to a 5 min treatment with MDMA (10 µg/mL).  No change in GFP-hSERT in either the 
cell surface or intracellular fraction was seen in HEK-293 cells after treatment with Bis I. 
Similarly there was no change in GFP-hSERT after 30 min with Bis I, followed by a 60 min 
with MDMA (10 µg/mL) (Figure 5:9).  
N2A cells expressing GFP-hSERT were also treated with the PKC inhibitor, Bis I.  Pre-
treatment with Bis I for 30 min was followed by of MDMA (10 µg/mL) treatment for 5 or 60 
min showed no detectable change in GFP-hSERT cell surface expression (Figure 5:10).   
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Figure 5:9: No change seen in GFP-hSERT expression after BisI and/or MDMA 
treatment in HEK-293 cells.   
HEK-293 cells were treated with either 200 nM BisI for 30 min, or treated with Bis I 
followed by MDMA (10 µg/mL) for 60 min.  There was no detectable change in cell surface 
expression after treatment with any of the compounds. DMSO was used as the vehicle 
control.  Shown is a representative gel for GFP-hSERT and Western blot for GAPDH below. 
T = total fraction, I = intracellular fraction, C = cell surface fraction (n = 8).  Data is 
presented as average ± SEM.  One-way ANOVA followed by Bonferroni post test showed no 
significant differences from the control. 
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Figure 5:10: No change seen in GFP-hSERT expression following Bis I and/or MDMA 
treatment in N2A cells.   
N2A cells were treated with either 200 nM Bis I for 30 min, or with Bis I followed by 
MDMA (10 µg/mL) for 60 min. There was no detectable change in cell surface expression 
after treatment with any of the compounds. DMSO was used as the vehicle control.  Shown is 
a representative gel for GFP-hSERT and Western blot for GAPDH below. T = total fraction, I 
= intracellular fraction, C = cell surface fraction (n = 4-9).  Data is presented as average ± 
SEM.  One-way ANOVA followed by Bonferroni post test showed no significant differences 
from the control. 
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5.3.3 Total Internal Reflection Fluorescence Microscopy (TIRFM) 
5.3.3.1 HEK-293 
5.3.3.1.1 SERT Trafficking in Response to MDMA 
Due to the limitation regarding the sensitivity of cell surface biotinylation techniques a more 
sensitive technique was employed called TIRFM.  TIRFM experiments were initially carried 
out for 300 s (5 min) with addition of MDMA (10 µg/mL) occurring at 50 s and images taken 
every 5 s.  Results show that MDMA had no immediate effect on SERT re-distribution during 
this time course as no change in surface expression was seen after MDMA treatment (Figure 
5:11). 
5.3.3.2 N2A 
5.3.3.2.1 SERT Trafficking in Response to MDMA and PKC Activation 
TIRFM experiments were extended to cover a time course of 600 s (10 min) to ensure that 
the time point where MDMA exerts its maximal effect was not being missed.  Results 
obtained from these experiments show that there is a trend towards a decrease in SERT 
surface expression following MDMA treatment (10 µg/mL) (Figure 5:12).  Two-way 
ANOVA showed that interaction was at statistical significance (p<0.0001), but time and 
treatment were both non-significant (p< 0.7108 and p< 0.1208 respectively).  It is interesting 
that cell surface biotinylation experiments did not show this trend. 
Due to the trend seen after MDMA treatment, N2A cells expressing GFP-hSERT were treated 
with β-PMA for 30 min.  This experiment was carried out before cell surface biotinylation 
showed that co-treatment with ionomycin and β-PMA causes a decrease in SERT surface 
expression (Figure 5.8). TIRFM experiments were carried out for 40 min, with either vehicle 
or 1 µM of β-PMA added at 10 min and treatment lasting for 30 min.  The results show that 
there was no significant change in cell surface fluorescence of GFP-hSERT following β-
PMA treatment (Figure 5:13).    
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Figure 5:11: MDMA does not significantly alter cell surface expression of GFP-hSERT 
expressed in HEK-293 cells.   
TIRFM was conducted on HEK-293 cells expressing GFP-hSERT.  70 images were taken, 5 
s apart, with MDMA (10 µg/mL) or vehicle being added at time 0.  No detectable changes in 
cell surface expression was seen (n = 8-9).  Average fluorescence was measured for each cell 
captured at each image and normalized back to the image taken at time 0. Vehicle used was 
PBS.  Data is plotted as the average ± SEM.  Two-way ANOVA followed by Bonferroni post 
test.  Shown is a representative MDMA-treated cell with images taken at -50, 0, 150 and 300 
s.  AFU = Arbitrary fluorescence units. 
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Figure 5:12: Cell Surface Expression of GFP-hSERT during 10 min incubation with 
MDMA in N2A cells.   
TIRFM was conducted with N2A cells expressing GFP-hSERT.  120 images were taken 5 s 
apart, with MDMA (10 µg/mL) or vehicle added at time 0.  There was a trend towards a 
decrease of GFP-hSERT at the cell surface after MDMA treatment (n = 5-7).  Average 
fluorescence was measured for each cell at each image captured and normalized back to the 
image taken at time 0. Vehicle used was PBS.  Data is plotted as the average ± SEM.  Two-
way ANOVA followed by Bonferroni post test was.  Shown is a representative MDMA-
treated cell with images taken at -50, 0, 300 and 600 s. 
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Figure 5:13: Cell Surface Expression of GFP-hSERT during a 30 min incubation with 
β-PMA in N2A cells.   
TIRFM was conducted on N2A cells expressing GFP-hSERT.  40 images were taken 1 min 
apart, with vehicle or β-PMA (1 µM) being added after 10 min.  No change was detectable in 
cell surface expression with β-PMA.  (n= 5-12 cells from 4 separate transfections). Average 
fluorescence was measured for each cell at each image captured and normalized back to the 
image taken at time 0.  Data is plotted as the average +/- SEM.  Two-way ANOVA followed 
by Bonferroni post test was carried out for statistical significance.  Shown is a representative 
β-PMA-treated cell with images taken at -10, 0, 10 and 30 min. 
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5.4 Discussion 
Previous studies have shown that PKC activation (Jayanthi et al. 2005) and MDMA treatment 
(Battaglia et al. 1987) decreases SERT function in cultured cells and rat brain tissue.  One 
way in which decreases in transporter function can occur is through decreased cell surface 
expression.  It has already been shown that activation of PKC by β-PMA leads to a decrease 
in surface expression of SERT both in vivo (Jayanthi et al. 2005) and in vitro (Bauman et al. 
2000).  Previous findings from our lab (Kivell et al. 2010) have identified that SERT cell 
surface expression is also decreased by application of MDMA in cultured cells.  We 
hypothesized that MDMA activates PKC, therefore causing an increase in SERT 
phosphorylation, leading to a decrease in 5-HT transport due to internalization of the 
transporter into the intracellular compartment.   
Neurochemistry experiments from Chapter 4 show a significant decrease in SERT function 
after both MDMA and β-PMA treatment in transfected HEK-293 and N2A cells.  RDEV can 
be used for kinetic studies, providing additional information on how SERT is being 
modulated by MDMA. A decrease in Vmax with little or no change in Km indicates a decrease 
in cell surface expression.  For GFP-hSERT transfected HEK-293 cells, initial velocities were 
kinetically resolved with Vmax values for MDMA treated and vehicle treated calculated as 
87.6 ± 43.1 pmol/s/10
6
 cells and 108.3 ± 33.5 pmol/s/10
6
 cells, respectively (Table 5:1).  
However the statistical analysis on these values showed that this was a non-significant 
decrease in SERT surface expression after MDMA treatment compared to control.  Statistical 
analysis was carried out on the Km values obtained for each treatment (3.3 ± 1.6 for control 
treated cells and 5.7 ± 3.7 for MDMA treated cells) with no significant difference calculated. 
However the size of the standard error for all of these values is quite large which could 
contribute to the lack of statistical significance.  Further repeats of the data would be ideal as 
this would resolve the error size, creating a tighter data set.  The values obtained for both 
Vmax and Km still fall within the range of values reported in the literature for transfected cell 
preparations.  Km values have been shown to fall between 0.3 µM (Zhu et al. 2005; Mao et al. 
2008; Tsuruda et al. 2010) and 21.8 µM (Mochizuki et al. 2005) which is quite a large range.  
This could be due partly to the various cell types used and different SERT plasmid expressed 
in the cell lines, as well as the different techniques used to generate kinetic data.   
The most puzzling aspect of this study is the kinetic data generated for the non-transfected 
and hSERT transfected N2A cells.  There is no current literature published for the use of 
RDEV in investigating SERT function in N2A cells.  This makes it challenging to interpret 
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the sigmoidal nature of the kinetic data set obtained.  One hypothesis is that we are measuring 
a mixture of SERT and non-SERT mediated 5-HT uptake.  In a recent publication carried out 
by Hagan et al. (2011), they focused on the contribution of low-affinity, high-capacity 
transport mechanisms for 5-HT clearance in synaptosomes using RDEV.  Through the use of 
a specific SERT blocker (paroxetine) and an inhibitor of low-affinity, high-capacity 
transporters (decynium-22, D-22), they found that at high 5-HT concentrations (>300 nM 
there was a large amount of non-SERT mediated uptake.  At low 5-HT concentrations (<300 
nM), both SERT- and non-SERT mediated mechanisms were observed for 5-HT uptake.  
They suggest that there may be low-affinity, high-capacity transporters present that may play 
a role in 5-HT uptake.  As N2A cells are neuronally derived it is possible that they express 
these other transporters, and they are contributing to 5-HT uptake as measured by our RDEV 
experiments. This could help explain the non-saturated region of the curve, leading to a 
sigmoidal shape.  Further investigation into this possibility was beyond the scope of this 
project but it is a very important future direction and would help support the conclusion that 
non-SERT mediated 5-HT uptake may have a significant biological importance.  There are 
several other studies that support the existence of alternative mechanisms of 5-HT uptake 
besides SERT.  For example, Grundemann and colleagues were the first to clone the organic 
cation transporters (OCTs) in the early 1990s.  These transporters are widely distributed in 
the brain and belong to the SLC22 family and act to take up cations and regulate salt intake. 
OCTs are capable of 5-HT uptake at high substrate concentrations such as the ones used in 
our study, and they have also been shown to be sensitive to MDMA (Amphoux et al. 2006; 
Koepsell et al. 2007; Daws 2009).  The OCTs have a much lower affinity for 5-HT compared 
to SERT; however, they are capable of high-capacity 5-HT transport (Busch et al. 1996; 
Daws et al. 2005).  The affinity of MDMA for the OCTs has been reported to be comparable 
to its affinity for SERT (Mortensen et al. 1999; Amphoux et al. 2006).  This raises the 
possibility that some of the effect MDMA has may be mediated by the OCT transporter, and 
until their role is further investigated in N2A cells, we cannot conclude that the kinetic data 
generated in this study is solely due to SERT-mediated 5-HT uptake. Another transporter 
capable of taking up monoamines is the plasma membrane monoamine transporter, PMAT 
(Engel et al. 2004; Dahlin et al. 2007).  Although it is not homologous with the other 
monoamine transporters, it does have capability for 5-HT uptake.   As reported by Engel et 
al. 2004, the transport efficiency of PMAT (Km and Vmax) in cell expression systems is only 
slightly different to that of SERT (2-3 magnitudes lower for Km but 2-3 magnitudes higher 
for Vmax).  This suggests that PMAT is a low affinity transporter but has high capacity for 5-
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HT uptake.  Presence of low-affinity, high-capacity 5-HT transporters could shift the Km 
value higher (Daws 2009; Hagan et al. 2011).   
Since the kinetic data from the RDEV experiments do not show a significant change in Vmax 
values, we cannot confirm that the functional change seen in Chapter 4 with MDMA 
treatment is due to a change in cell surface expression.  Two other techniques that provide 
detail on surface expression changes are cell surface biotinylation and TIRFM. Cell model 
studies published from our lab show that cell surface biotinylations and TIRFM experiments 
have been used successfully to show that treatment with MDMA causes an internalization of 
SERT from the cell surface in transfected HEK-293 and N2A cells (Kivell et al. 2010).  
Similarly, this study showed that PKC activation by β-PMA causes an internalization of 
SERT from the cell surface in transfected in HEK-293 cells. The cell surface biotinylation 
results showed that MDMA and β-PMA down-regulates SERT from the plasma membrane of 
HEK-293 cells by 24% and 23% respectively.  TIRFM studies show that MDMA has a rapid 
effect on SERT surface expression in HEK-293 cells, with a significant decrease seen at 290 
s and sustained until 420 s with a 13% decrease (Kivell et al. 2010).  Unexpectedly, in this 
study, no change in cell surface expression of SERT was detectable with cell surface 
biotinylations in the HEK-293 cell line after a 60 min treatment with MDMA (Figure 5:5).  A 
10 min treatment with MDMA was also investigated with no significant change in cell 
surface expression of SERT (Figure 5:5).  The TIRFM experiments confirmed that MDMA 
was not having an effect on SERT surface expression in HEK-293 as no change in surface 
fluorescence was observed (Figure 5:11).  This became of some concern that HEK-293 cells 
were not responding to MDMA treatment in the predicted manner, so experimental focus was 
shifted to N2A cells.  An explanation for this possibility is that HEK-293 cells of varying 
passage numbers (up to 100 passages) were utilized throughout the experiments which may 
affect the stability of the cell and cause them to be significantly diverged from their parent 
line.  Three time points for MDMA treatment were investigated (5, 10 and 60 min).  Even 
though RDEV results from Chapter 4 show that MDMA has a functional effect on SERT 
after 5 and 10 min, a 60 min time point was included in the cell surface biotinylation 
experiments in this study.  This is due to the fact that findings from our lab show that MDMA 
has a sustained effect on decreasing cell surface expression of SERT and to ensure that time 
of maximal activity of MDMA on SERT was not being missed unexpectedly.  When no 
significant change was observed in cell surface expression of SERT in the cell biotinylations 
in any of the time points (Figure 5:6), TIRFM experiments were carried out. From these 
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results it appears that there is a trend towards a decrease in cell surface expression of SERT 
after MDMA (10 µg/mL) treatment for 10 min (Figure 5:12).  Due to time constraints this 
trend could not be investigated further; however, it would be ideal to gather a larger data set 
to confirm the trend.  The main concern when choosing representative cells to analyze in the 
TIRFM experiments is the amount of cell movement that is encountered due to drifting.  
Since the evanescent field was set to only 100 nm from the coverslip, if the cell was not 
adhered properly to the bottom of the dish, it had the tendency to drift either away or closer to 
the surface throughout the time course.  This is a concern as it could create false impressions 
of the fluorescence measured for SERT trafficking.  For HEK-293 cells especially, this was a 
significant problem encountered.  Coating the glass-covered dishes with poly-d-lysine helped 
to eliminate some of this movement by improving the adherence of cells to the culture dish.   
Treatment with 1 µM β-PMA did not cause any detectable change in cell surface expression 
of SERT as indicated by cell surface biotinylation experiments in HEK-293 (Figure 5:7) or 
N2A cells (Figure 5:8) transfected with GFP-hSERT.  Testing a new solution of β-PMA also 
did not show a significant change in cell surface expression as indicated by cell surface 
biotinylation experiments for the two cell lines (Figure 5:7 and Figure 5:8) and TIRFM for 
N2A cells (Figure 5:13).  This was the most surprising result, as it is well published that β-
PMA activates PKC which causes an internalization of SERT (Jayanthi et al. 2005; Samuvel 
et al. 2005; Kivell et al. 2010).  For N2A cells, when ionomycin was applied in conjunction 
with β-PMA, there was a significant decrease (35% compared to control-treated cells) in cell 
surface expression of SERT (p<0.001) (Figure 5:8). Ionomycin is known to cause an increase 
in intracellular calcium levels, and for β-PMA-induced activation of PKC, it is necessary to 
have calcium present (Samuvel et al. 2005). Previous studies have shown that the presence of 
intracellular calcium is essential for the amphetamine-mediated stimulation of PKC activity 
in the dopaminergic system.  Rat synaptosomes treated with a calcium chelator showed that a 
depletion of intracellular calcium resulted in the attenuation of dopamine release induced by 
amphetamine treatment (Giambalvo 2003). Further studies using ionomycin in conjunction 
with β-PMA in TIRFM experiments would be essential to investigate this trend further.  
Unfortunately due to product availability and time constraints further investigation into 
treatment with ionomycin could not be carried out.  
There is no clear explanation for why these two techniques, cell surface biotinylation and 
TIRFM, did not show a detectable change in cell surface expression of SERT after MDMA or 
β-PMA treatment.  For cell surface biotinylation it must be emphasized that the sensitivity of 
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the technique may not be high enough to detect possible changes in surface expression of 
SERT in this particular study.  As mentioned before, the intracellular fraction can be 
overestimated due to biotin not being able to bind proteins found in membrane invaginations 
(Furman et al. 2009).  For TIRFM experiments it must be pointed out that, depending on 
where the SERT is located on the surface of the cell, it can be differentially modulated 
(A.Sorkin, personal communication).  SERT located on the filopodia of the cell is modulated 
rapidly, compared to SERT located on the surface of the cell body.  Expression levels varied 
between individual cells even in the same transfection and though efforts were made to 
choose cells for analysis that displayed similar expression levels of SERT, variation in 
expression could have an effect on the level of regulation. It must be kept in mind that 
presence of 5-HT attenuates β-PMA-induced activation of PKC.  While HEK-293 and N2A 
cells are not commonly reported to contain endogenous 5-HT, it must be stated that there is 
one report which indicates that immunoblots of HEK-293 cells show that have been 
identified as positive for the presence of the SERT gene and 5-HT (Shaw et al. 2002).  The 
amounts found were of minimal concentrations and there have been no further studies to 
suggest the presence of 5-HT in HEK-293 or N2A cells. 
There is one previous study carried out by Wang et al. (2005) that did not report any change 
in expression levels between the cell surface and intracellular compartments of SERT after 
MDMA administration.  They suggest that MDMA exposure may result in less SERT being 
associated with lipid rafts.  SERT that are not associated with lipid rafts are non-functional 
and this could account for the results showing that MDMA is able to decrease SERT function 
without altering expression levels.  However this study was carried out with antibodies to the 
SERT protein, and identification of SERT from the immunoblots must be carried out with 
caution as SERT antibodies have been shown to be non-specific (refer to Chapter 3 for 
detailed discussion). 
Whether MDMA targets a PKC-dependent pathway to exert its effect on SERT is still 
unknown.  PKC inhibition by Bis I treatment was carried out in parallel on GFP-hSERT 
transfected HEK-293 and N2A cells.  This was in the hopes to see if Bis I could prevent the 
predicted internalization of SERT from the cell surface into the intracellular fraction after 
MDMA treatment. Unfortunately, since the cell surface biotinylations and TIRFM results are 
not conclusive about whether MDMA or PKC activation causes a decrease in SERT cell 
surface expression in this study, we cannot state that PKC inhibition prevents MDMA-
induced internalization.  The kinetic information gathered from the RDEV experiment in this 
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chapter are also inconclusive about whether the down-regulation in SERT function seen in 
Chapter 4 after MDMA treatment and PKC activation in HEK-293 cells is due to a change in 
cell surface expression.  An increase in Km normally suggests a decrease in monoamine 
uptake, where a decrease in Km suggests an increase in uptake.  Decreases in Vmax without a 
significant change in Km signifies that the transporter is down-regulated from the cell surface, 
either by a decrease in cell surface expression, or modulation by post-translational 
modifications, similarly an increase in Vmax suggests an up-regulation of the transporter.  
However a combined increase in both Km and Vmax can signify an up-regulation of the 
transporter in some circumstances (Meiergerd et al. 1994). It is not clear whether a combined 
decrease in the kinetic values could be indicative of a down-regulation of the transporter. 
There is a non-significant decrease in the Vmax value for MDMA-treated HEK-293 cells 
compared to control without a significant change in Km values.  Since the cell surface 
biotinylations nor TIRFM experiments suggest a change in cell surface expression, it could 
be concluded that that SERT is being functionally altered rather than through a trafficking-
dependent mechanism such as internalization in this particular study.   
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6 Chapter 6: Final Discussion 
SERT is an important part of the brains natural reward pathway and is a major target for 
drugs of abuse such as MDMA.  Previous studies have shown that SERT expression on the 
cell membrane is down-regulated after exposure to MDMA (Kivell et al. 2010).  SERT 
regulation is tightly controlled by a large network of kinases which cross-talk with each 
other, creating an efficient 5-HT signaling system.  Changes in the phosphorylation state of 
SERT have been shown to trigger internalization from the plasma membrane, leading to 
changes in trafficking and function of the transporter.  Dysregulation of this system is 
implicated in disease states such as depression and anxiety and SERT is known to be 
involved in substance abuse (Green et al. 2003).  How MDMA interacts and exerts its effects 
on the signaling molecules responsible for the regulation of SERT at the cell membrane 
would help to narrow the gap in scientists’ current knowledge about how drugs of abuse act 
on the monoamine systems.  The neurotoxic action of MDMA is highly disputed throughout 
the literature, and although this subject was not a key focus in this study, advances in 
information about how MDMA targets SERT for down-regulation may provide a stepping 
stone for further investigation into its mechanism of action.  This is important for 
understanding how drugs of abuse are able to modulate their targets and could lead to 
pharmacotherapies for reversing the effects of drugs of abuse or preventing drug-induced 
cellular changes. 
p38 MAPK is a well-known regulator of SERT, however previous research from our 
laboratory has suggested that MDMA does not exert its effects on SERT through this 
particular kinase (Kivell et al. 2010).  This was shown through a series of experiments which 
demonstrated activation of p38 MAPK was not related to MDMA-induced SERT down-
regulation from the cell membrane.  This has led to investigation of other well-known 
regulatory proteins of SERT.  PKC is known to directly regulate SERT through 
phosphorylation, causing a loss of cell surface expression and corresponding decrease in 5-
HT uptake (Jayanthi et al. 2005).  Studies using the PKC activator, β-PMA, have shown that 
SERT is regulated in a biphasic manner, with short treatments of less than 30 min causing a 
decrease in 5-HT transport.  Longer treatments exceeding 30 min result in a loss of SERT 
expression from the cell surface (Jayanthi et al. 2005).  This phosphorylation event occurs on 
as-yet unknown serine and threonine residues.  The RDEV technique that was utilized in this 
study allowed for an in-depth investigation into whether MDMA was targeting a PKC-
dependent pathway in order to down-regulate SERT.  RDEV data from HEK-293 cells 
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expressing GFP-hSERT has suggested that MDMA is able to activate PKC and cause a 
down-regulation in SERT function by decreasing 5-HT uptake (Figure 4:4).  Further 
investigation using RDEV into whether MDMA was causing SERT internalization in a 
similar PKC-dependent manner resulted in a non-significant change in Vmax and Km values 
for control-treated vs. MDMA-treated HEK-293 cells expressing GFP-hSERT (Table 5:1).  
Since one of the major ways SERT is regulated is through changes in cell surface expression, 
this data is surprising.  Both cell surface biotinylation and TIRFM experiments did not show 
a significant change in SERT surface expression after PKC activation (Figure 5:7, Figure 5:8 
and Figure 5:13) or MDMA treatment (Figure 5:5, Figure 5:6, Figure 5:11 and Figure 5:12), 
contrary to previous studies (Jayanthi and Ramamoorthy 2005; Kivell et al. 2010).  It was 
through trouble-shooting that addition of ionomycin with β-PMA to N2A cells expressing 
GFP-hSERT caused a significant 35% decrease in the cell surface expression of SERT 
(Figure 5:8).  Unfortunately due to time constraints and product availability, further 
experiments could not be carried out with TIRFM or RDEV using ionomycin. This suggests 
that these cell lines are dependent on the presence of intracellular calcium in order to carry 
out correct regulation of SERT. 
Unfortunately there were unexpected results arising from this study, one including the 5-HT 
uptake sigmoidal dose-response curve generated by N2A cells expressing GFP-hSERT 
(Figure 5:3).  This experiment needs further investigation to validate the results presented 
here and for a more in-depth understanding of the cellular system that was studied.  For now, 
we hypothesize that N2A cells generate both SERT-mediated and non-SERT mediated 5-HT 
uptake.  The redundancy and plasticity of the SERT uptake system is well-known.  The 
ability of transporters to take up other molecules beside their cognate substrates was 
highlighted in the 1960’s when studies confirmed that catecholaminergic neurons were able 
to accumulate 5-HT (Daws 2009).  Later studies showed that DAT was able to take up and 
release 5-HT (Stamford et al. 1990; Wightman and Zimmerman 1990).  While there is no 
doubt that SERT is the primary regulator for 5-HT uptake, it must be noted that alternative 
mechanisms do play a role, and can come into play when 5-HT levels are high or when SERT 
function or expression is impaired or absent (Daws 2009).  OCTs and PMATs are two classes 
of alternative transporters that have the ability to transport 5-HT.  Whether these transporters 
are present in N2A cells and are involved in 5-HT uptake is unclear and requires further 
investigation. 
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Using the information found in the literature and combining it with the data from this study, 
we make an attempt to propose a model for how MDMA regulates SERT.  After translation 
SERT starts off in a non-glycosylated, non-phosphorylated form at an unidentified molecular 
weight.  N-glycosylation begins in the Endoplasmic Reticulum and is completed in the Golgi 
apparatus.  This is followed by phosphorylation carried out by at least p38 MAPK which 
provides the basal phosphorylation level to trigger the SERT to insert into the membrane.  As 
seen by cell surface biotinylation experiments in this study (see Chapter 5), we identify this 
as the 103 kDa band.  Upon MDMA exposure, PKC is activated and phosphorylates SERT 
on a serine residue.  This is aided by a rise in intracellular calcium levels and causes a 
conformational change in SERT, leading to a decrease in 5-HT transport.  This 
conformational change has been identified through studies investigating 5-HT binding 
(Murphy et al. 2004), and so is possible that MDMA causes a similar conformational change.  
It is possible that the 75 kDa band seen solely in the intracellular compartment of the 
biotinylation experiments is a non-glycosylated non-functional form of SERT.  The 103 kDa 
band however, is found in both the intracellular and cell surface fractions.  It is possible that 
it is this form of SERT which becomes internalized after further phosphorylation on a 
threonine residue by PKC. 
6.1 Future directions: 
Further investigation into the relationship between MDMA and PKC and how they affect 
SERT function is needed before certain conclusions can be drawn.  If indeed MDMA targets 
PKC to cause a down-regulation in SERT function it would be intriguing to use a 
biochemical colourimetric assay kit to determine the level of activity MDMA induces in 
PKC.  Transfecting a cell line such as HEK-293 cells would be ideal as they are easy to 
manipulate and they express the necessary signaling pathways.  Basal activity levels of PKC 
could be compared to the PKC activity after cells expressing SERT are exposed to MDMA.  
If MDMA is working through a PKC-dependent pathway then it would be expected that PKC 
activity increases in order to target SERT for internalization and subsequently decreasing 5-
HT transport. 
Another angle that could be pursued is the generation of SERT mutants.  Knockout of 
specific residues such as serine or threonines could provide information on the site that 
MDMA targets which triggers the functional down-regulation and internalization of SERT.  
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Identification of the SERT bands could be an alternative future direction.  By using mass 
spectrometry it would be possible to elucidate the primary sequence of the two major bands 
(103 kDa and 75 kDa) that we identify as SERT.  This could help identify areas of post-
translational modification, and differences in glycosylation or phosphorylation between the 
two SERT forms.  
What would be intriguing to further investigate is the presence of low-affinity high-capacity 
transporter systems that may exist in both HEK-293 cells and N2A cells.  Treatment using D-
22 as an inhibitor of low-affinity, high-capacity transporters would provide further insight 
into the presence of transporters such as OCT’s and PMAT. This would be interesting to 
explore to what extent the role they play in 5-HT uptake.  Determining the biological 
significance of these alternative transporters could provide insight on how they function as 
novel mediators of 5-HT uptake which would be important for developing further 
understanding of human disease.   
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7 Appendix 1: Solutions 
 
Biotinylations 
10x Phosphate Buffered Saline (PBS) pH 7.4 
 
 
 
 
PBS was made by dissolving the salts into 900 ml of ddH2O.  The solution was then adjusted 
to pH 7.4 by addition of concentrated HCl or NaOH.  1x PBS (0.15 M) was prepared from 
this stock and autoclaved as required. 
1x PBS Ca/Mg pH 8.0 
Reagents g/L 
CaCl2 0.111 
MgCl2.6H2O 0.203 
 
Salts were dissolved in 1x PBS, with the pH being adjusted to pH 8.0 using concentrated 
HCL or NaOH. 
1x PBS Ca/Mg/Glycine 
Reagents g/L 
CaCl2 0.111 
MgCl2.6H2O 0.203 
Glycine 75 
 
 
 
 
Reagents g/L 
NaCl 80 
KCl 2 
Na2HPO4 26.8 
KH2PO4 2.4 
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Westerns 
Radio-immuno-precipitation assay (RIPA) buffer (100 mL) pH 7.5 
Reagents mg/100 mL 
Tris-HCl 121.1 
NaCl 876.6 
EDTA 37.22 
TritonX-100 1 mL 
SDS 100 
Sodium deoxycholate 1000 
 
Ingredients were mixed to final volume of 100 mL using ddH2O, and pH was adjusted to 7.5 
with 1 M HCl. 
10x Tris Buffered Saline (TBS) 
Reagents g/L 
Tris 60.5 
NaCl 87.6 
 
Salts were dissolved in 800 mL ddH2O and pH adjusted to 7.5 using concentrated HCl.  Final 
volume was made up to 1 L using ddH2O. 
1x Tris Buffered Saline-Tween 20 (TBST) 
TBST was prepared by addition of 1 mL Tween-20 to 1L of 1x TBS buffer. 
Western Blot Transfer Buffer 
Reagents g/L 
Tris 3.03 
Glycine 14.4 
SDS 0.38 
Methanol 150 mL 
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Ingredients were mixed in 850 mL of ddH2O and chilled in 4ºC.  Methanol was added 
directly before use. 
Stripping Buffer 
Reagents g/500 mL 
SDS 10 
0.05M Tris-HCl 496.25 mL 
β-Mercaptoethanol 3.75 mL 
 
Ingredients were mixed together with pH adjusted to 6.8 with concentrated HCl. 
10x SDS Running Buffer 
Reagents g/L 
SDS 10 
Tris 30.3 
Glycine 144.1 
 
Ingredients were dissolved in 1 L of ddH2O. 
5x Reducing Buffer (10 mL) 
Reagents  
1.5M Tris pH 6.8 1 mL 
10% SDS 5 mL 
80% Glycerol 3.2 mL 
1% Bromphenol Blue 0.8 mL 
 
Ingredients were mixed together and 1 mL aliquots were stored at -20ºC. 
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10% SDS Polyacrylamide Separating Gels 
(2 gels- 1.5 mm thick) 
Reagents  
ddH2O  
1.5 M Tris-HCL pH 6.8  
10% SDS in ddH2O  
Acrylamide/Bis 6.66 mL 
10% Ammonium persulphate (APS) 100 µL 
TEMED 10 µL 
 
Ingredients were added in order shown.  10% APS and TEMED were added last to initiate 
polymerisation of acrylamide.  The gel solution was then used to fill the gel casting apparatus 
and overlaid with 100% isopropanol.  The gel was left to set for a minimum of 45 minutes.  A 
4% stacking gel was then placed on top after removal of the isopropanol. 
4% SDS Stacking Gel 
Reagents  
ddH2O  
1.5 M Tris-HCL pH 8.8  
10% SDS in ddH2O  
Acrylamide/Bis 1.33 mL 
10% Ammonium persulphate (APS) 50 µL 
TEMED 10 µL 
 
Plasmid Preparation 
LB-Broth  
Reagents g/L 
Tryptone 10 
NaCl 10 
Yeast Extract 5 
 
Ingredients were mixed together to a final volume of 1 L in ddH2O.   
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LB-Agar (200 mL) 
Reagents g/200 mL 
Tryptone 2 
NaCl 2 
Yeast Extract 1 
Agar 2 
 
Ingredients mixed together in a final volume of 200 mL dH2O.  Autoclaved, left to cool, 
addition of antibiotic, pour plates, 12.5 ml each plate, left to set for a minimum of 45 min. 
Kanamycin (50 mg/mL) 
To make a 50 mg/ml stock of Kanamycin, add 0.5 g of Kanamycin to 10 ml of ddH2O.  
Aliquot out in 1 mL and store at -20C.  Working solution in experiments is 50 µg/µl. 
RDEV 
KREB Buffer 
 
 
 
 
 
 
Reagents g/L 
NaCl 7.6 
KCl 0.10 
CaCl2 0.24 
MgSO4.6H2O 0.27 
KH2PO4 0.16 
HEPES 2.6 
D-Glucose 1.8 
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8 Appendix 2: BCA Protein Assay 
To determine the amount of protein to load for the SDS-PAGE gels, protein assays were 
carried out on all samples for the Western blot experiments.  A set of BSA (bovine serum 
albumin) standards were diluted so that the absorbance of a range of concentrations were 
measured to create a standard curve.  A sample from either transfected or non-transfected 
lysates were taken from each cell line and diluted either 1:10 or 1:100 and the absorbance 
measured along with the standards.  A representative curve is shown below where the 
absorbance value for each lysate is compared to that of the standard curve so the 
concentration can be calculated using the equation derived from the graph.  A range of 2.5 – 
50 µg/20 µL well was loaded on an SDS-PAGE gel. 
 
 
Figure 8:1 Standard curve for BCA assay.   
The equation derived from the standard curve generated by the BSA standards was used to 
determine the unknown protein concentration of the lysate samples.  The absorbance 
(denoted by y) of all samples was measured at 562 nm, with the values being plotted against 
the protein concentration of the BSA standards (denoted by x). 
y = 1.0163x + 0.1044 
R² = 0.9955 
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